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Abstract 
Stereotactic Body Radiation Therapy (SBRT) is an effective treatment option for patients 
with inoperable early-stage lung cancer.  SBRT uses online image-guidance technology [e.g. 
cone-beam CT (CBCT)] to focus small-fields of high energy x-rays onto a tumour to deliver 
ablative levels of radiation dose (e.g. 54 Gy) in a few treatment fractions (e.g. 3).  For the 
combination of these treatment parameters and a low density lung, lateral electron 
disequilibrium (LED) can potentially occur, reducing lung and tumour doses.  The goal of 
this thesis was to determine the impact of LED on stereotactic body radiation therapy for 
lung cancer. 
 The effect of LED on lung dose distribution was studied using Monte Carlo 
simulations of a lung slab phantom.  The magnitude of lung dose reduction due to LED, and 
the specific conditions (beam energy, field size, and lung density) that cause the 
phenomenon, were quantified and could be predicted using a relative depth dose factor 
(RDDF). 
 The RDDF concept was then used to develop a novel SBRT technique, called LED-
optimized SBRT (LED-SBRT), which creates steep dose gradients, caused by intentional 
LED, to elevate tumour dose, while reducing/maintaining dose levels in healthy lung.  
Further, the RDDF aided in assessing the accuracy required in CBCT-derived lung density, 
when applied to adaptive SBRT dose calculations.  In this regard, we determined that CBCT 
image artefacts produced erroneously low lung density, artificially triggering LED, and 
incorrectly predicting lower lung/tumour dose levels.  As a result, CBCT number corrective 
techniques were developed in order to improve dose calculation accuracy. 
 The results of this thesis provide physicians and physicists with a much better 
prediction of the radiation dosimetry under disequilibrium conditions, and allow exploration 
of irradiation conditions that can cause LED.  With this knowledge in-mind, competent 
decisions can be made regarding the choice of dose calculation algorithm, and aid in the 
design and interpretation of SBRT clinical trials.   Furthermore, the outcomes of this work 
can help launch a new generation of SBRT techniques that exploit LED effects that may 
offer dosimetric benefits for selected patients. 
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Chapter 1  
1 Introduction 
1.1 A Clinical Case 
Figure 1-1 depicts a CT scan of a middle-aged patient who presents with a small lung 
lesion (~ 1 cm in diameter) located within the middle lobe of the right lung.  No evidence 
of mediastinal nodal or distant metastases is reported by the radiologist.  This patient 
represents a typical lung cancer patient with stage T1 N0 M0 (early-stage tumour without 
nodal involvement or metastases).  In Canada, this type of patient represents 1 of 25,600 
individuals diagnosed with lung cancer in 2012 [1].  Treatment of lung cancer remains 
very challenging, where the mortality rate is approximately 40%, highest among all forms 
of cancers.  Currently, patients such as the example reported in Figure 1-1 have two 
major options for treatment: (1) surgery or (2) radiation therapy. Each has its advantages 
and disadvantages in terms of tumour control and risk of treatment complications. 
 
 
 
Figure 1-1 displays an axial slice from a 4-dimensional computed tomography (4D-CT) 
study of the sample patient.  A small lung tumour is apparent in the right lung (left side of 
the image). 
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1.2 Surgery versus Conventional Radiation Therapy 
Surgery is regarded as a very good option for patients presenting with early-staged lung 
cancer.  In this case, the tumour is physically resected from the lung, resulting in 
excellent tumour control (tumour control probability (TCP) > 90% [2]).  However, if the 
patient is a long-term cigarette smoker, and presents with other co-morbidities such as 
chronic obstructive pulmonary disease (e.g. emphysema and bronchitis), heart disease, 
frailty, and overall poor health, the patient may not be healthy enough to tolerate the 
invasive nature of open chest surgery [3].  In fact, only 10% of all lung cancer patients 
diagnosed with non-small cell lung cancer (NSCLC) are eligible for such surgery [4], 
despite the development of less invasive endoscopic procedures like video-assisted 
thorascopic surgery [5].  If the patient depicted above is unfit for surgery, 3-dimensional 
conventional radiation therapy (3D-CRT) is a potential treatment option. 
 3D-CRT involves multiple beams of x-ray radiation overlapped onto a tumour 
volume in order to deliver a high dose of radiation (e.g. 60 Gy), over many treatment 
sessions (e.g. 2 Gy per day x 30 days).  See Figure 1-2 for example. 
Figure 1-2: displays the additive dose from three overlapping fields of radiation focused 
onto a thoracic tumour.   The coloured straight lines indicate the individual beams of 
radiation.  The ‘colour wash’ (also shown with brighter iso-dose lines) indicates the dose 
distribution with drop-off outside the tumour region. 
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For patients with early-staged lung cancer who receive 3D-CRT, typical prescription 
doses range between 55-70 Gy extended over a 4 to 7 week period [6].  Unfortunately, 
this dosage schedule produces poor TCP levels of only 30% to 40% [7], and 5 year 
survival rates of only 20% [8].  Martel et. al. demonstrated that by escalating the tumour 
dose to 84.5 Gy (delivered in once-daily 2 Gy fractions) the TCP could be improved to 
50% [9]. Other studies have attempted to escalate tumour dose in hopes of improving 
TCP, overall survival rates, and reducing local tumour recurrence rates [10, 11, 12].  
However, endeavors to increase dose levels within the thorax must be weighed against 
the possibility of producing associated lung toxicity.  In particular, the percent volume of 
lung tissue receiving an absolute dose ≥ 20 Gy (i.e. the V20), and the average absolute 
dose within healthy lung tissue [i.e. mean lung dose (MLD)] are of utmost importance for 
avoiding toxicity in lung radiotherapy [13, 14].  When these lung dose metrics are 
exceeded, complications such as radiation pneumonitis, fibrosis, and even death can 
occur [15].  Thus, in the absence of a highly effective treatment alternative, the sample 
patient shown in Fig. 1-1 may choose to forego treatment altogether; a decision that is 
associated with extremely poor prognosis [16].  As such, oncologists and medical 
physicists began to seek out better “high dose” radiation treatment alternatives for 
patients afflicted by early-staged lung cancer.  
 
1.3 Stereotactic Body Radiation Therapy (SBRT) 
1.3.1 Development of SBRT 
Stereotactic radiosurgery (SRS) was developed during the time period spanning the1940 - 
1960s, and was solely used to treat cancerous malignancies of the central nervous system 
(e.g. brain) [17].  Radiosurgery is a non-invasive technique that uses single, high dose 
fractions of radiation (e.g. 24 Gy in one exposure) to ablate intracranial tumours.   With 
SRS, high doses of radiation could be used to effectively control malignant disease while 
sparing surrounding healthy brain tissue [18].  However, great beam precision was 
required to target the tumour, which was facilitated through the use of auxiliary imaging 
modalities, fiducial markers, and a stereotactic frame to immobilize the skull [19] during 
4 
 
radiation exposure.  Extracranial stereotactic radioablation techniques were later 
developed to treat cancerous sites in other regions of the body (e.g. abdomen) [20].   
 It appears that SRS could be adapted to treat patients with early-staged lung 
cancers who are not candidates for surgery.  However, the translation of the SRS 
treatment technique from the brain to lung is not simple for two major reasons: 1) tumour 
mobility, and 2) more complex radiation dosimetry in low-density heterogeneous lung 
tissue.  The process of human respiration causes the expansion and contraction of the 
thoracic cavity creating geometric as well as densitometric changes.  Lung tumours can 
move centimeters in various directions, and these displacements may push the tumour 
beyond the field edges of the radiation beams.  This is highly undesirable since portions 
of the tumour will be under irradiated, while surrounding lung tissue will be over 
irradiated.  How then do we target a small, mobile tumour with a focused ablative dose of 
radiation?  The answer to this question came through advancements in four-dimensional 
diagnostic computed tomography (4D-CT). 
 
1.3.2 Improved imaging techniques facilitate SBRT in lung  
A typical 3-dimensional CT (3D-CT) system can be used to create volumetric images of 
patient anatomy.  However, 3D-CT may be insufficient to scan the human thorax due to 
artefacts caused by respiratory motion during the scan.  The motion of the tumour and 
diaphragm can cause image artifacts within 3D-CT reconstructions that greatly 
complicate tumour volume definition as well as subsequent treatment delivery [21].  One 
way to overcome this challenge is to acquire a 4D-CT image of the lung patient’s thorax 
[22, 23]. A 4D-CT is essentially a 3D movie that can be used to determine the in vivo 
trajectory of a lung tumour over the course of respiration (see Figure 1-3). 
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 With 4D-CT scanning, the entire patient breathing cycle is broken into a sequence 
of breathing phases; for each phase, a 3D-CT image is created that portrays the tumour 
and the thoracic cavity’s position over a small time range.  Using this information, it is 
conceivable to design a radiation treatment plan that accounts for lung tumour motion.  
However, additional imaging technology is required to align the radiation fields’ 
isocentre with the tumour’s center of mass at the time of treatment.  This process can be 
performed accurately using image-guided radiation therapy (IGRT). 
 
1.3.3 CT image-guided SBRT 
IGRT combines the radiation treatment capabilities of a linear accelerator (LINAC) with 
some form of imaging modality into a single amalgamated design.  Commonly, this is 
done in a radiotherapy setting by mounting a cone-beam CT (CBCT) scanner onto a 
LINAC (see Figure 1-4).  With CBCT technology, a time-averaged CT volume of the 
patient’s thorax can be acquired, which can be used to portray the tumour motion 
envelope, and patient anatomy just before delivering the next session of radiation 
treatment [24].  Further, 4D-CT and gating technology allow for the treatment planning 
Figure 1-3: on the left, a single slice 3D-CT sagittal image of a lung cancer patient. 
Tumour motion produces an image artifact where three artificial small tumour volumes 
appear to be present in the lung.  On the right, two 4D-CT images (sampled at maximum 
exhale and inhale) show there is actually one tumour volume moving along the superior-
inferior axis of the lung. 
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and delivery of radiation to occur during a single or multiple phases of patient respiration 
[25].  Currently, CBCT technology allows SRS treatment fields to be accurately focused 
onto a lung tumour (i.e. patient set-up), reducing misalignment between patient tissues 
and radiation beam to within 2 mm of static tissues [24].   
 
 
 In addition to facilitating patient set-up, IGRT hypothetically could be used to 
adapt radiation treatment planning and delivery in accordance with previous deformations 
within patient tissues, which otherwise cannot be resolved by simply re-aligning the 
patient or moving the treatment couch.  This process of continually refining the delivered 
dose distribution in accordance with patient tissue deformation is called image-guided 
adaptive radiation therapy (IGART; see Figure 1-5 below). With IGART it is possible to 
adaptively modify the tumour target margins and dose distribution to best accommodate 
changes in patient anatomy.  Also, any deviations in the accumulating delivered dose 
from intended dose can be accounted for by modifying treatment delivery in future 
fractions.  However, adaptive modification of the dose distribution requires accurate dose 
calculation methods and high-fidelity tissue electron density information derived from 
image-guidance technology, which brings to question the suitability of cone-beam CT for 
on-line IGART. 
 
Figure 1-4 displays a Varian On-board Imaging cone-beam CT (CBCT) unit mounted 
onto a linear accelerator (LINAC).  The auxiliary x-ray source and detector are used to 
form CBCT images.  Adapted from Ding et al., 2007 [63] 
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 CBCT images are composed of voxels (or volume elements) that are assigned a 
specific CBCT number in accordance with tissue attenuation (in Hounsfield Units or 
HU).  CBCT thorax images are subject to artifacts (or apparent flaws in CT numbers) 
such as cupping (dark artificially hypo-dense image regions) and streaking (lines of 
hyper/hypo-dense image regions), which are due to the broad-beam scanning geometry 
[26], and patient respiration during slow scan times (some of these artefacts can be seen 
in Figure 1-6, which shows the corresponding CBCT image of the patient displayed in 
Figure 1-1) [27, 28].   Thus, CBCT number data within patient lung tissue can be 
misleading, and electron density information derived from CBCT numbers used directly 
for dose calculations can be inaccurate.  The extent to which these resultant density 
inaccuracies impact adaptive SBRT dose calculations is not known.  This is a major topic 
of interest in this thesis.  
 
 
Figure 1-5: the future of image-guided radiation therapy is image-guided adaptive 
radiation therapy (IGART).  In this paradigm, online CBCT information is used in a 
closed feedback loop to adaptively re-plan the radiation treatment fields in accordance 
with daily organ deformations and tumour changes.  Patient set-up errors can also be 
avoided through couch shifts.  
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1.4 SBRT in Lung and Dose Escalation  
With advances in imaging and radiation treatment technologies, it became plausible to 
treat extracranial tumours using the SRS technique [29].  In particular, for target sites 
within the thorax, the radiotherapy community has coined a new term entitled stereotactic 
body radiation therapy (SBRT), or stereotactic ablative radiotherapy (SABR).  SBRT has 
prompted a significant change in radiation therapy for early-staged lung cancer patients.  
Dose escalation is now possible with prescription radiation doses of 48-60 Gy delivered 
in only 3 to 8 fractions [this corresponds to biologically effective doses (BED) ≥ 100 Gy, 
which is ablative (i.e. comparable to surgical removal)].  Total treatment time can now be 
reduced to within a 2.5 week timeframe.  This hypofractionated treatment paradigm has 
many postulated advantages: 1) short treatment times counter potential tumour cell 
repopulation, and 2) large doses per fraction may overcome ineffective tumour cell kill 
rates due to hypoxic (oxygen deficient) tumours, if re-oxygenation between fractions 
occurs [30].  Clinically, the advantages of SBRT are now evident in better outcomes for 
patients.  Where dose is localized and sufficiently large, many trials have shown that TCP 
can be on the order of 90% with low levels of related toxicities [31, 32, 33, 34, 35]. 
 With modern-day SBRT, there is an opportunity to further escalate the tumour 
dose in order to boost TCP beyond the 90% level.  However, increased tumour dose must 
Figure 1-6 displays the cone-beam CT (CBCT) image of the patient depicted in Fig. 1-1.  
Note the apparent cupping and streak artifacts, which are the visual results of inaccurate 
underlying CBCT number data. 
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not come at the expense of over-irradiating surrounding healthy lung tissue.  Novel SBRT 
techniques should be developed in order to increase tumour dose levels, while at least 
maintaining the lung dose to currently well-tolerated levels.  Unfortunately, one major 
road block impeding this development is a lack of knowledge concerning the complex 
radiation dosimetry of SBRT fields within heterogeneous lung tissue.  SBRT of early-
staged lung cancer uses high energy, small radiation fields to irradiate tumours embedded 
within low density lung.  For these treatment conditions, a physical phenomenon called 
lateral electron disequilibrium (LED) may occur, which reduces the energy absorbed by 
lung and tumour tissues exposed to a small-field of radiation. This effect can also occur at 
the beam edge and media interfaces.  To exacerbate this issue further, modern day 
treatment planning systems (TPS) may not adequately account for these unusual physical 
effects.  These issues are better explained after briefly reviewing the radiation physics 
relevant to SBRT of early-staged lung cancer. 
 
1.5 Radiation Physics of Lung Dosimetry 
1.5.1 KERMA, and KERMAc 
This topic has been described in detail by The American Association of Physicists in 
Medicine (AAPM) Report Number 85 [36].   We begin with a distribution of photon 
fluence impinging on the surface of a patient.  As photons traverse through the tissues of 
the body, their probability of attenuation (or interaction) per unit distance is given by the 
linear attenuation coefficient, µ (µ = [cm
-1
]).  µ depends on the effective atomic number 
(Zeff) and density (ρ = [g/cm
3
]) of the tissue, as well as the incident photon energy (MeV). 
 In a radiotherapy beam, each photon has an associated energy (MeV), and the 
collection of photons reaching a point within a patient determines an energy fluence, Ψ 
(MeV/cm
2
).  Thus, at a particular location within the patient, the total energy released per 
unit mass (i.e. TERMA), is given as the product of the mass attenuation coefficient (µ/ρ) 
and the energy fluence at that point: 
       (
 
 
)      (1.1) 
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The kinetic energy released only to charged particles (e.g. electrons) per unit mass is 
defined as KERMA (KERMA < TERMA).  From KERMA we define another subset 
entity known as KERMAc, or the collisional KERMA (KERMAc < KERMA).  KERMAc 
is the kinetic energy released to charged particles per unit mass and subsequently 
absorbed locally along these charged particle tracks. 
 
1.5.2 Charged Particle Interactions, Equilibrium, and Dose 
1.5.2.1 Photon and Electron Interactions with Tissue 
In the radiotherapeutic energy range (0.1 MeV – 18 MeV), there are three primary 
photon-tissue interactions that contribute to KERMAc: the photoelectic effect, Compton 
interaction, and pair production.  The predominance of each interaction depends on both 
the photon energy and absorber Zeff.  For instance, in water-like tissues (Zeff ~ 7.5) the 
Compton interaction dominates over the energy range from 0.05 MeV to 10MeV. 
 The photon-tissue interactions impart kinetic energy to recoil charged particles, 
such as Compton electrons.  Once launched, electrons experience Coulombic collisions 
along their path length, which converts kinetic energy into ionization and excitation 
events within the medium.  The mass collisional stopping power, Scol, [37] can be used to 
describe the rate of local energy deposition by an electron along its path length:  
    
 
 
  
   
 ; (
       
 
)     (1.2) 
Where an average rate of energy (  ) is lost locally per unit path length (    and per 
density of medium (ρ).  The range or path length, R, of an electron can be estimated from 
    
 
 by integrating it over the slowed-down electron energies.  
1.5.2.2 Charge Particle Equilibrium (CPE) and Lateral Electron 
Disequilibrium (LED) 
The concept of charged particle equilibrium or CPE is central to this thesis.  CPE occurs 
when the energy of electrons upon entering and leaving a small dosimetric volume are 
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equal [36].  Under CPE, partial electron tracks are complementary and can be summed to 
form a complete range (R).  The situation is as if the energy actually deposited along a 
complete track is instead entirely absorbed ‘on the spot’.  When CPE holds, the details 
concerning electron transport can be ignored in dose calculations, and the dose (D) 
becomes simply equal to the KERMAc: 
                 (1.3) 
Pure CPE can only occur when the photon and electron fluence is uniform across the 
sampling volume.  In practice, these conditions are never met because of beam 
divergence and photon attenuation [38].  
 Transient charged particle equilibrium (TCPE) on the other hand is achievable, 
and the dose becomes proportional rather than equal to the collision KERMA. TCPE is a 
3D concept, and can occur along the central-axis of a photon field if electron equilibrium 
is maintained in both the longitudinal and lateral directions (the longitudinal direction 
being parallel the central-axis of the radiation beam).  For example, at shallow beam 
depths (below the maximum longitudinal electron range), longitudinal electron 
disequilibrium exists, which produces the characteristic ‘dose build-up’ region in depth 
dose profiles.  Similarly, for depths beyond the maximum longitudinal electron range, 
lateral electron disequilibrium (LED) occurs when the lateral range of electrons becomes 
equal or greater than the radius of the field.  Under this circumstance, electrons liberated 
from the radiation beam’s central-axis will scatter beyond the field edge, and they are not 
replaced, which reduces the dose along the beam’s central axis (see Figure 1-7).  LED 
clearly depends on the radiation field size, beam energy, and medium density [39].  As a 
general rule, the lateral range of electrons is approximately 1/3 the longitudinal range in 
water.   However, the lateral electron range can expand for higher beam energies incident 
upon lower density mediums (e.g. lung), as is the case for radiosurgery beams.  With 
small fields incident on lung densities (0.1 g/cm
3
 up to 0.4 g/cm
3 
[40, 41]), we have the 
“perfect storm” for LED, and simplified dose calculation techniques are inadequate with 
regard to SBRT of early-staged lung cancer. 
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Radiation Source 
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   Water Medium Lateral plane 
Electrons 
Figure 1-7 (a) depicts a photon source impinging on a water medium.  Photons traverse 
through water until attenuated, where they liberate electrons.  The electron trajectory is 
tortuous (shown as a curvy red line), but can eventually passes through point Q depositing 
dose there.  Electron range can be viewed to have longitudinal and lateral components.  
The lateral component is observed in Fig. 1-7 (b), where a slice through the water is used 
to depict the LED concepts. For TCPE conditions, outwardly scattered electrons (blue 
arrow) are replaced by inwardly scattered electrons (green arrow), maintaining the energy 
equilibrium at Q.  For LED conditions, outwardly scattered electrons (red arrow) travel 
beyond the field radius and cannot be replaced (as no photon fluence exists beyond the 
field edge), resulting in an energy imbalance, which reduces dose along the central-axis of 
the beam (at Q). 
(a) 
 
 
Q 
Beams Eye View of Lateral Plane 
Beam edge 
(b) 
Longitudinal axis 
Lateral axis 
Q 
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1.5.3 Dose Calculation Algorithms 
Dose calculation algorithms can be classified in accordance with their ability to treat 
TERMA and electron scatter separately.  Two general designations will be described 
below: 1) local energy deposition and 2) non-local energy deposition. 
 
1.5.3.1 Local energy deposition algorithms 
Dose calculation algorithms in this category intrinsically assume CPE, i.e., energy is 
absorbed ‘on the spot’, as opposed to along the entire electron range.  As a result, these 
algorithms do not account for the dosimetric effects of LED, and can overestimate the 
lung/tumour dose distribution by as much as 30% for SBRT treatment conditions [42].  
These techniques are generally no longer used in commercial software for treatment 
planning. 
 
1.5.3.2 Non-local energy deposition algorithms 
Models have been developed that focus on the transport of secondary electrons away 
from photon interaction sites.  These typically involve convolution and/or superposition 
algorithms [43, 44, 45], or the Monte Carlo (MC) method [46, 47], which explicitly 
scores energy deposition along each electron track set in motion by numerous photon 
collisions.  In the context of convolution or superposition algorithms, the initial sites of 
primary photon interaction are viewed as ‘sources’ of energy, and point kernels map the 
‘spreading’ of energy away from the interaction site.  For a radiotherapeutic photon 
beam, a downstream shower of secondary radiation (scattered photons and electrons) 
originates from every site of primary photon interaction within patient tissues and the 
convolution process sums their overall effect.  In the presence of inhomogeneities, the 
attenuation of the primary photon fluence and the scope of dose kernel ‘spread’ are 
altered.  For example, within lung tissue (ρ ~ 0.25 g/cm3), the local primary photon 
fluence is generally enhanced due to reduced tissue attenuation, but conversely the dose 
kernel expands in size due to extended particle ranges. 
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For SBRT treatment conditions in lung, where charged particle equilibrium is mildly 
disrupted (e.g. 6 MV beams), convolution algorithms can produce sufficiently accurate 
dose results within a range of 1-4% [48, 49, 50, 51, 52, 53].  However, for 
radiotherapeutic conditions involving more severe charged particle disequilibrium – high 
beam energies (18 MV), small field sizes (< 5x5cm
2
), and low densities (<0.4 g/cm
3
) 
[51]– dose discrepancies as high as 8% have been reported [54].  More accurate 
calculations can then be obtained with the MC method. 
 Monte Carlo is a stochastic algorithm, which can be used to simulate the behavior 
of physical processes where analytical solutions fail and measurements are too difficult.  
The MC technique exploits well-known probability distributions that govern fundamental 
radiation interactions.  For example, in order to simulate the transport of an x-ray through 
patient tissues, three sampling steps are required: 1) distance to interaction, 2) type of 
interaction (photoelectric, Compton, pair production), and 3) determination of the angular 
and energy distribution of secondary particles (scattered x-rays and electrons).  
Secondary particles are also followed through tissues until their energy is exhausted, or 
escapes the patient altogether.   One possible combination of multiple events (stemming 
from steps 1-3) is called a ‘history’.   For each history, the energy absorbed locally within 
patient tissues can be ‘scored’ within voxels.  When a sufficient number of histories is 
simulated, MC generated dose distributions are extremely accurate.  As such, MC results 
have been used to bench mark many different dose calculation techniques for 
circumstances involving charged particle disequilibrium [39, 49, 50, 51, 55, 56, 57, 58].  
Unfortunately, the computational requirements of typical MC codes (e.g. DOSXYZnrc 
[National Research Council of Canada, Ottawa, ON]) are extensive, and calculation times 
have traditionally been too long for use in a clinical setting.  However, recent innovations 
in computer processing power (e.g. graphics processing units) and parallel computation 
techniques have produced accurate MC dose calculations within seconds [59], and MC 
based TPSs are now becoming comercially available [e.g. Cyberknife stereotactic 
radiosurgery system (Accuray Inc., Sunnyvale, CA) [60]].   
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1.6 Research Problems, Questions, and Hypothesis 
SBRT of early-staged lung cancer involves delivering ablative levels of radiation dose in 
only a few treatment sessions.  With advancements in imaging and radiation treatment 
technologies, there is an opportunity to develop novel SBRT techniques to further 
increase lung tumour dose levels, which may improve tumour control and overall 
survival rates.   Unfortunately, SBRT treatment conditions in lung (MV x-rays, small 
fields, and low density) are more apt to disrupt CPE, which perturbs the delivered dose 
distribution in the tumour and lung tissues.  Modern day CBCT densitometry and dose 
calculation algorithms do not address extreme LED conditions appropriately.   Previous 
authors focused on the inability of dose calculation algorithms to predict the dosimetric 
effects of LED, but failed to explore the full range of radiotherapeutic (RT) conditions 
[50, 51, 52, 53, 54, 55, 56, 58, 48].  A study on this topic may help to elucidate these RT 
conditions, which is useful for clinicians looking to avoid LED or select appropriate dose 
calculation algorithms for SBRT clinical trials.  In addition, this information would be 
useful in the development of novel SBRT techniques that can exploit correctly-predicted 
LED, focused on increasing tumour dose, while at least maintaining and/or reducing 
normal lung dose to safe levels.  In order to address these issues, we have therefore 
formulated the following research questions: 
1. What combination of radiation field size, energy, and lung density will cause the LED 
phenomenon to occur? 
2. How sensitive is the dose distribution in LED regions to CT-derived lung density? 
3. How do we design a new SBRT technique that forces LED to occur in order to produce 
“spikes” of highly localized dose in small tumours, relative to surrounding lung?   
In addition to the issues described above, the implementation of adaptive SBRT currently 
faces many practical challenges.  Online image-guidance technology (e.g. cone-beam 
CT) undoubtedly allows for accurate alignment of the radiation treatment fields with the 
tumour’s location.  Furthermore, CBCT images could also be used for online dose 
calculations in order to adapt radiation treatment parameters in accordance with observed 
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organ deformations.  However, today’s CBCT images of the thorax contain erroneous CT 
number information, which contribute to dosimetric errors in the adaptive SBRT process 
[61, 62].  However, no explanation has been provided to date that expands on relevant 
physics behind these density-driven errors, or their magnitude. These research problems 
lead to the next set of questions for the thesis: 
4. How does CBCT-derived lung density affect the lung and tumour dose distribution? 
5. Are lung cone-beam CT numbers correctable for the purpose of accurate dose 
calculation? 
The answers to these questions are highly inter-related, and depend upon core 
consideration of the LED phenomenon.  The thesis hypothesis is thus stated as follows: 
The accurate delivery of image-guided adaptive stereotactic body radiation therapy for 
lung cancer requires due consideration of the potential effects of charged particle 
disequilibrium (CPE and LED).  
 
1.7 Research Plan and Objectives 
The work presented in this thesis is focused on three main topics and their 
interdependency: 1) stereotactic body radiation therapy (SBRT) of early-staged lung 
cancer, 2) the radiation physics of photon energy deposition within lung tissue 
[specifically, concepts involving charged particle equilibrium (CPE) and lateral electron 
disequilibrium (LED)], and finally, 3) image-guided radiation therapy (IGRT) using 
online cone-beam CT (CBCT) for adaptive SBRT of lung cancer.  These topics are 
displayed in Figure 1-8 with regions labeled by the letters A (SBRT and physics in lung; 
coloured red), B (SBRT and IGRT; coloured blue), C (physics and IGRT; coloured 
green), and D (union of all three topics; coloured purple).  Three primary research 
objectives were developed in order to study these main topics and their co-dependency: 
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1.  Using a Monte Carlo simulation of a lung slab phantom, determine the 
 combination of radiation beam energy, field size, and lung density that causes a 
 sudden drop in lung dose, indicating loss of CPE (region A in Figure 1-8). 
2. To develop a new SBRT technique, denoted as LED-optimized SBRT, which 
 utilizes radiation therapy parameters designed specifically to cause LED in order 
 to greatly reduce normal lung dose, while increasing dose levels within the 
 tumour volume (region A in Figure 1-8). 
3. To assess the magnitude of densitometric errors in CBCT images of the thorax 
 due to CBCT geometry, slow scan times, and patient respiratory motion [region B 
 in Figure 1-8].  
4. To determine the extent of dosimetric error due to erroneous CBCT number data 
 for adaptive SBRT of early-staged lung cancer (region C in Figure 1-8). 
 
 
 
 
 
 
 
Figure 1-8 A schematic introducing the major topics to be addressed within this thesis.  
Correlations between these topics are demarked by the letter A (    ⋃       ; red 
region), B (    ⋃    ; blue region), C (       ⋃     ; green region), and D 
(    ⋃       ⋃     ; purple region). 
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1.8 Thesis Outline 
1.8.1 A Monte Carlo study of the impacts of LED on Stereotactic 
Body Radiation Therapy (Chapter 2) 
This chapter is adapted from the research article, "An in-depth Monte Carlo study of 
lateral electron disequilibrium for small fields in ultra-low density lung: implications for 
modern radiation therapy" published in Physics in Medicine and Biology, 2012, March 
21;57(6):1543-59 by Disher B, Hajdok G, Gaede S, Battista JJ.  This chapter uses Monte 
Carlo simulations of multiple virtual lung phantoms to determine the radiotherapeutic 
parameters necessary to disrupt CPE, creating LED (Region A; see Figure 1-8).  Over 
1000 dose calculations were performed by varying different combinations of beam 
energy (Co-60 up to 18 MV), field size (1x1cm
2
 up to 15x15 cm
2
), and lung density 
(0.001 g/cm
3 
up to 1 g/cm
3
).  From this analysis, a new clinical tool was developed as a 
predictor of LED, referred to as the Relative Depth Dose Factor (RDDF).  The RDDF can 
be used to indicate the extent of LED (RDDF<1) or electronic equilibrium (RDDF ≥ 1).  
For example, when RDDF < 0.7, LED was severe and caused reductions of both the lung 
and tumour dose distribution.  In general, dose reductions were the worst when small 
tumours were irradiated with high beam energies, small field sizes, and low lung density 
(as is the case for SBRT of early-staged lung cancer).   This study contains new 
knowledge that is useful for radiation oncologists who wish to avoid the negative 
dosimetric effects of LED, which is crucial for the design and interpretation of SBRT 
clinical trials.  Further, chapter 2 explains the physical effects of lung density on 
radiotherapy dose calculations.  This information is valuable for interpreting how 
erroneous CBCT-derived lung density influences adaptive SBRT dose calculations 
(Chapter 4).  Also, this data aided in the development of new a SBRT technique that uses 
LED to advantage (Chapter 3). 
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1.8.2 LED-SBRT: a novel SBRT technique used to spare lung 
tissue from radiation exposure (Chapter 3) 
This chapter is adapted from the research article, "Forcing Lateral Electron 
Disequilibrium to Spare Lung Tissue: A novel technique for stereotactic body radiation 
therapy of lung cancer", accepted pending revisions, Physics in Medicine and Biology, 
2013, submitted April 16, by Disher B, Hajdok G, Gaede S, Mulligan M, and Battista JJ.  
In this chapter, Monte Carlo simulations of both a phantom and lung patient are used to 
demonstrate a new SBRT technique, LED-optimized SBRT (LED-SBRT), which utilizes 
tailored radiation therapy parameters (determined from Chapter 2) to cause LED to 
advantage (Region A; see Figure 1-8).  LED-SBRT creates extremely steep dose 
gradients at the lung/tumour boundary.  This highly heterogeneous dose distribution can 
be used to reduce normal lung dose, while increasing dose levels within a tumour 
volume.  For example, LED-SBRT was used to increase the patient’s maximal, mean, 
and minimal tumour dose by as much as 80Gy, 11Gy, and 3Gy, when compared to a 
more conventional SBRT plan.  Despite elevated tumour dose levels, LED-SBRT was 
also able to provide sufficient tumour dose coverage, while maintaining or lowering 
commonly used lung dose metrics (e.g. mean lung dose, V5, and V20).  These results are 
important as increased tumour dose may improve tumour control probability, while lower 
lung dose metrics may reduce the chances of radiation lung injury (e.g. pneumonitis and 
fibrosis).   
 
1.8.3 Assessing the suitability of cone-beam CT thorax images for 
SBRT and dose adaptive radiation therapy (Chapter 4) 
This chapter is adapted from the research article, "Correction for “artificial” electron 
disequilibrium due to cone-beam CT density errors: Implications for on-line adaptive 
stereotactic body radiation therapy of lung" published in Physics in Medicine and 
Biology, 2013 Jun 21;58(12):4157-74 by Disher B, Hajdok G, Wang A, Craig J, Gaede S, 
and Battista JJ.  In this chapter, we assess the suitability of CBCT thorax images for 
SBRT of three typical early-staged lung cancer patients (region B; see Figure 1-8).  The 
accuracy of CBCT number data, and resultant dose distributions, were compared to 
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planning CT (PCT) based information.  For example, it was determined that CBCT lung 
image artifacts (cupping, streaking, and blurring) erroneously reduced CBCT derived 
lung density compared to PCT data.  The dosimetric effect of erroneously low CBCT 
lung density was to artificially create LED, which incorrectly reduced the lung and 
tumour dose compared to PCT results (region C; see Figure 1-8). These findings were 
interpreted by applying the RDDF, and knowledge of LED physics derived from Chapter 
2.  Further, using this knowledge, we proposed appropriate CT number corrective 
techniques to improve CBCT image-based dose calculation accuracy for dose adaptive 
SBRT of early-staged lung cancer patients (region D; see Figure 1-8).   
 
1.8.4 Conclusions (Chapter 5) 
In the last chapter, the main findings from chapters 2-4 are summarized.  Also, a separate 
section is dedicated to potential future projects that could stem from this thesis.   
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Chapter 2  
2 An in-depth Monte Carlo study of lateral electron 
disequilibrium for small fields in ultra-low density lung: 
implications for modern radiation therapy 
This chapter is adapted from the research article, "An in-depth Monte Carlo study of 
lateral electron disequilibrium for small fields in ultra-low density lung: implications for 
modern radiation therapy" published in Physics in Medicine and Biology, 2012, March 
21;57(6):1543-59 by Disher B, Hajdok G, Gaede S, Battista JJ. 
 
2.1 Introduction 
Lung cancer is a leading cause of cancer related death worldwide [1].  A growing number 
of patients are being diagnosed with earlier stage lung cancer, as a result of increased use 
of diagnostic computed tomography (CT) scans [2].   Traditional radiation therapy (RT) 
can be used to treat these patients, but long term survival rates remain low (16%) [3].  A 
more promising technique, known as stereotactic body radiation therapy (SBRT), has 
been shown to improve local control of these types of lung tumours [4].  SBRT uses 
tightly conformed Megavoltage (MV) x-ray fields to irradiate the tumour at high dose 
levels using few fractions, and with less damage to adjacent normal lung tissue.  As well, 
with the advent of image-guided radiation therapy (IGRT) it is possible to reduce planned 
margins around tumour volumes, shrink radiation field sizes, and escalate dose.  As a 
result, modern technologies such as intensity modulated radiation therapy (IMRT) are 
now frequently using sub-centimeter MV photon fields for radiation therapy. [5] 
     Human lung density can be abnormally low (≤ 0.1 g/cm3) for emphysematous 
lung [6], and up to 0.35 g/cm
3 
for healthy lung tissue [7]. For this range of densities the 
dose distribution is affected by two competing factors: 1) a reduction of photon 
attenuation, and 2) enhanced secondary electron range.  When secondary electron 
equilibrium is maintained, reduced photon attenuation is the dominating factor, and dose 
is increased within the lung and tumour tissues [8] compared with dose in an all-water 
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absorber.  In the absence of electron equilibrium, in the lateral/transverse direction, large 
reductions of the dose distribution occur in lung [9, 10]. For instance, Aarup et al., 2009 
used Monte Carlo simulations to virtually irradiate a lung phantom containing a 2 cm 
diameter spherical tumour with an 18 MV x-ray beam [11].  By reducing the lung density 
from 0.4 to 0.1 g/cm
3
, they showed that the mean target dose decreased from 83.3 to 
61.6% (relative to water density), respectively. Large dose variations within lung and 
tumour tissues are possible, and accurate dose algorithms must be chosen to account for 
these effects.  More importantly, clinical trials that do not include any (or include an 
inaccurate) correction for lung density will yield ambiguous results because the tumour 
doses will vary for a given dose prescription “in water”. 
  Dose calculation algorithms can be generalized into two broad categories based 
on energy deposition modeling [12]. The first category (1) assumes that charged particle 
equilibrium is always maintained, and it’s as if energy deposition occurs “on the spot” of 
photon interaction; there is no modeling of secondary electron transport.  The Modified 
Batho [13] and equivalent tissue-to-air ratio [14] techniques all fall into this category.  
The second category (category 2) assumes non-local energy deposition and considers 
electron transport. Superposition/Convolution [15] methods like the Collapsed Cone 
Convolution (CCC) [16] and Analytic Anisoptropic Algorithm (AAA) [17] analytically 
model electron transport, while Monte Carlo techniques [18] explicitly track electron 
transport.  The MC approach is generally considered the gold standard for determining 
dose distributions for circumstances of electron disequilibrium, and where interpretations 
of dosimetric measurements are challenging.  As such, it has been used by many authors 
to bench mark the accuracy of different dose calculation techniques [11, 19, 20, 21, 22, 
23, 24, 25]. 
 It has been shown that category 1 dose algorithms overestimate the amount of 
dose deposited in lung and tumour tissues under the conditions of lateral electron 
disequilbrium (LED) [10, 11, 26, 27, 24, 25].  For instance, Engelsman et al., 2001 
compared the dose calculating accuracy of multiple category 1 algorithms (pencil beam, 
modified Batho, and equivalent path length) with film and ion chamber measurements. 
Beam energies of 6, 8, 15, and 18 MV were used to irradiate a 50 mm polystyrene target 
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centrally contained within a lung slab, simulated by cork. Their results show that the 
three algorithms predict up to 20% higher dose levels in the lung and tumour compared 
with the actual delivered dose values.  As well, the error in dose calculation increased 
with photon beam energy [26].   
 The ability of category 2 algorithms to accurately compute dose in lung tissue has 
been assessed by multiple authors.  Most studies suggest that type 2 algorithms (AAA 
and CCC) are superior to type 1 methods for calculating dose when electron equilibrium 
is not maintained [11, 20, 21, 28, 24, 25].  However, Tillikainen et al., 2008 showed that 
the AAA algorithm produced errors up to 8% in lung tissue when using small field 18MV 
x-rays to irradiate a phantom [17].  A more recent comparison of CCC and MC by Chow 
et al., 2009 suggest that the CCC algorithm produced significant dose deviations in lung 
phantoms and patients for treatment parameters using high energy beams, small field 
sizes, and low lung density (< 0.3 g/cm
3
) – the usual conditions that ruin electron 
equilibrium [29]. 
 Summarizing the literature, it is evident that category 1 algorithms are inadequate 
for prediction of correct dose in SBRT or IMRT of lung cancer patients.  Category 2 
algorithms are generally better, but may still be challenged to produce accurate dose 
distributions under extreme LED due to oversimplification and assumptions in modeling 
of electron transport [23].  Despite this being an active field of research, no previous 
efforts have fully explored the range of radiotherapeutic parameters that can lead to 
unexpected LED in SBRT and other modern techniques.  Considering the range of 
treatment planning protocols and ambiguous dose prescriptions used in SBRT, a 
comprehensive study focused on this topic is justified and timely. 
 SBRT protocols set by Radiation Therapy Oncology Group (RTOG) trials [0236, 
0618, 0813, and 0915] are used to quantify the conformity and coverage of the dose 
delivered to the planning target volume (PTV). The PTV is defined by the gross tumour 
volume (GTV) plus a minimal expansion of approximately 0.5 to 1 cm into lung tissue.  
The beam aperture is forced to correspond to the beam’s eye view projection of the PTV.  
As a result, the iso-dose lines covering the periphery of the PTV typically range between 
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60 to 90%.  The prescribed dose (20 Gy per fraction x 3 fractions for example) is 
typically set to the 80% iso-dose shell located at the edge of the PTV within lung tissue.  
This arrangement forces a hot spot (≥ 100% of the prescription dose) to occur within the 
central region of the tumour.  Lastly, to ensure that the high dose volume is contained in 
the vicinity of the tumour, the ratio of the volume of the prescription iso-dose to the 
volume of PTV should be < 1.2.  Similarly the ratio of the 50% iso-dose volume to the 
PTV must also conform to specific criteria, which depends on tumour volume.  These 
ratios will be discussed as the high and low dose volumes, respectively. 
 The treatment parameters used for SBRT of lung cancer patients are more apt to 
create LED.  The SBRT protocols discussed above may not be attainable using modern 
day dose algorithms, which are more susceptible to error under the conditions of severe 
LED.  Most importantly, the prescription dose is calculated from an iso-dose line within 
lung tissue where LED dose perturbations are greatest.  The actual delivered dose 
distribution may be drastically different from the dose predicted by a treatment planning 
system [30, 31, 32]. Therefore a thorough understanding of the combination of radiation 
treatment parameters that establish LED is essential for SBRT of lung cancer patients if 
one wishes to avoid the strong dose variations associated with LED. 
 Although LED in lung RT is well documented [29], most studies present a limited 
set of variations in beam energy, lung density, and field size.  The specific combinations 
of treatment conditions that create LED are not well known.  In this work we use the MC 
technique to fully characterize the parameters that establish LED.   This analysis includes 
energies from Co-60 up to 18 MV x-rays, including a wide range of clinically relevant 
field sizes (1x1 cm
2
 up to 15x15 cm
2
) and lung densities (0.001 g/cm
3
 up to 1 g/cm
3
).  
Additionally, we study the dosimetric effects on various small lung tumour phantoms 
under the conditions of LED.  Finally, the implications of this work are discussed in the 
context of SBRT and other forms of modern radiation therapy. 
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2.2 Methods 
2.2.1 Monte Carlo codes and parameters 
MC simulations were performed using EGSnrc, BEAMnrc, and DOSXYZnrc user codes 
(National Research Council of Canada, Ottawa, ON).  Simulations were conducted 
simultaneously using a PC-based computer cluster that consisted of 60 independent Intel 
Xeon central processing units (CPU).  The CPUs operated at processing speeds of 
2.67GHz or 3.4 GHz.  The total RAM available to the cluster was 102 GB. 
 BEAMnrc [55] was used to generate the phase space file for a Varian 21 EX 
linear accelerator (Varian Medical Systems Inc., Palo Alto, CA) 6 MV x-ray source (5x5 
cm
2
; field size at 100 cm source-to-axis distance).  The primary electron beam radius was 
set to 0.5 mm, and 1x10
8
 histories were used to create 5x10
6 
particles.  The variance 
reduction technique of selective bremsstrahlung splitting was used to increase 
computational efficiency.  The electron and photon cutoff energies were set as 521 keV, 
and 10 keV (i.e. ECUT and PCUT), and PRESTA II
 
[33] and EXACT were selected as 
the electron step and boundary crossing algorithms.  These settings were applied for both 
DOSXYZnrc and BEAMnrc user codes.  DOSXYZnrc was used to perform all dose 
calculations, and 1×10
8
 to 8×10
8
 histories were simulated.  The statistical uncertainty in 
dose voxels was less than 2% for all calculation points.  Also, all dose profiles were 
normalized to the maximum dose in water per beam and field size. 
2.2.2 Experimental validation of Monte Carlo simulation in low 
density material 
EGSnrc, BEAMnrc, and DOSXYZnrc user codes have been used extensively and 
validated in similar applications [23]. However, we wanted to establish the suitability of 
the MC technique for dose calculations in an ultra-low density medium.  To this effect, 
dose in air was measured using a slab phantom and the Varian 6 MV (5x5 cm
2
) source.  
These measurements were acquired with an A1SL Exradin miniature Shonka thimble ion 
chamber (Standard Imaging Inc, Middleton, WI), and results were compared to DOSXYZ 
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calculation results to validate the MC technique.  The experimental setup consisted of a 
slab geometry with 5 cm of solid water (Gammex RMI
®
, Middleton WI), then 10 cm of 
air, and followed by another 10 cm of solid water.  Similarly, DOSXYZnrc was used to 
simulate a slab phantom consisting of 20x20x25 cm
3
 volume with a voxel size of 
0.25×0.25×0.25 cm
3
.  The slab materials were set to H2O521ICRU (i.e. water, z = 0 .. 5 
cm), AIR521ICRU (i.e. air, z = 5 .. 15 cm), and H2O521ICRU (z = 15 .. 25 cm) [see Fig. 
2-1].  Dose was calculated using the previously discussed phase space file for the 6 MV 
input source. 
 
 
 
 
 
 
 
Figure 2-2(a) shows the central-axis depth-dose comparison between A1SL measurement 
and MC dose calculation.   In the water slab regions, there is excellent agreement 
between dose calculation and measurement with differences less than 2%.  In contrast, in 
the air region, MC dose is reduced by 31% to 36% compared to measurement.  
Measuring dose in air from a megavoltage photon field is challenging due to severe LED 
Figure 2-1 Schematic diagrams (not to scale) of the slab phantoms without tumour (shown 
left) and with tumour (shown right).  The cubic water tumour insert ranged in size from 
1x1x1cm
3
, 3x3x3cm
3
, and  5x5x5cm
3
.  Simulations included combinations of 6 photon 
sources, 5 field sizes, and 12 lung densities.  The lung insert was initially set to AIR521ICRU 
to validate the Monte Carlo dose calculation in a low density medium. 
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[34].  As well, the ion chamber is not totally air-equivalent, contributing 4mm of water 
build-up that perturbs the equilibrium conditions
 
[35]. 
To overcome this problem, we also used the MC method to simulate the material and 
geometrical specifications of the A1SL ion chamber from the manufacturer.  The A1SL’s 
shell, collector, guard material, and electrode stem were modeled in DOSXYZnrc and 
placed at central-axis depths of 1.5, 6, 8, 10, 12, and 14 cm within the slab phantom 
simulation; a separate dose calculation was made for each depth.  Figure 2-2(b) shows 
the central-axis depth-dose result comparing measurement to MC dose calculation using 
the modeled A1SL ion chamber.  Note that within the air slab, the difference between 
dose points is now reduced to less than 3%.  DOSXYZnrc can accurately model the dose 
perturbation in air when ion chamber materials are placed within the photon field. 
(a)  Without MC ion chamber model             (b) With MC ion chamber model  
Figure 2-2 compares the MC dose calculation to measurement using the A1SL ion chamber. In 
the air region the ion chamber perturbs the dose-to-air measurement, reporting erroneously 
high dose. In Fig. 2-2 (b), we modeled the ion chamber at different depths within the MC slab 
phantom, and calculated dose to air in the vicinity of the ion chamber; measurement and MC 
dose calculation were then in agreement. 
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2.2.3 Monte Carlo simulations of slab phantoms 
DOSXYZnrc was also used to study the effects of beam energy, field size, and lung 
density on dose distributions.  Four slabs phantoms were simulated all with identical 
geometry to the phantom discussed above, except that the air slab was replaced with 
LUNG521ICRU material.  The first phantom contained lung material only, whereas the 
second, third, and fourth phantoms also included a 1x1x1cm
3
, 3x3x3cm
3
, and 5x5x5cm
3
 
water cube insert (see Fig. 2-1).  The water cube was meant to mimic a small human 
tumour located centrally at a depth of 10 cm within the lung material, analogous to lung 
SBRT conditions.   
 To characterize LED in lung tissue, dose calculations were performed using 
photon distributions from therapeutic sources including: Co-60, 4MV, 6MV, 10MV, 
15MV, and 18MV spectra [36].  As well, the square field size of each beam was varied 
between 1x1cm
2
, 3x3cm
2
, 5x5cm
2
, 10x10cm
2
, and 15x15cm
2
.  The density of the lung 
slab was decreased from 1 to 0.001 g/cm
3 
(1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, 
and 0.001 g/cm
3
).  A total of 1440 simulations were performed for all combinations of 
beam energy, field size, and lung density (6 energies, 5 field sizes, 12 lung densities, and 
4 phantoms).  Dose was “scored” at depth along the central-axis of the phantoms into 
volume bins of 0.25×0.25×0.25 cm
3
 for each simulation.  Similarly, transverse-axis dose 
was also scored at a depth of 10 cm within the phantoms using the same sized volume 
bins. 
 
2.3 Results 
2.3.1 Monte Carlo simulations of slab phantoms; no tumour insert 
Figure 2-3 shows selected depth-dose and transverse-dose (at d = 10 cm) profiles for 
various lung slab densities, beam energies (1.25, 6 and 18 MV), and a 10×10 cm
2
 field 
size.  In Fig. 2-3 (a), (b), and (c) photon fluence was generally enhanced by decreasing 
the lung slab density, which increased the central-axis dose in and beyond the lung slab, 
as can be expected intuitively. However, for lung densities below the “critical density”, 
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LED occurs, and there is an observed sudden decrease lung dose.  For example, in Fig. 2-
3 (a) the critical lung density is 0.1g/cm
3
, and the central-axis depth-dose decreased by as 
much 46% (relative to water) for a density of 0.001 g/cm
3
.  Note for Fig. 2-3 (b) and (c), 
the critical densities are 0.1g/cm
3 
and 0.2g/cm
3
, respectively (not shown in Fig. 2-3).  For 
ultra-low densities (ρlung < 0.1 g/cm
3
), the lateral electron range of secondary electrons 
was significantly expanded, and became comparable or larger than the lateral beam 
radius (5 cm).  Electrons liberated from the central-axis of the beam escaped beyond the 
field edge, and could not be replaced, which reduced the central-axis depth-dose and 
increased the transverse-dose beyond the field edge.  The observed central-axis dose 
depression is the hallmark of severe lateral electron disequilibrium [29, 10, 36, 37, 23, 
38]. 
 Figure 2-4 displays similar results to those shown in Fig. 2-3 except the photon 
field size was reduced to 3x3cm
2
.  The critical lung densities extracted from Fig. 2-4 (a), 
(b), and (c) are 0.2, 0.4, and 0.7 g/cm
3
, respectively.  Note that LED occurs for higher 
lung densities than those reported in Fig. 2-3, which are in the range of clinically-
observed normal lung densities.  By shrinking the field size from 10×10 cm
2 
down to 
3x3cm
2
, the lateral range of secondary electrons required to establish LED is only 1.5cm, 
and electron transports previously inhibited by higher density lung can now reach the 
closer field edge.  As well, both Fig.s 2-3 and 2-4 demonstrate that higher beam energy 
imparts more kinetic energy to laterally scattered electrons, which can easily escape the 
beam periphery for lower density lung and smaller field sizes.     
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(a)      1.25 MV (10×10 cm
2
)   
  Depth-dose          Transverse-dose 
 
 
 
(b)      6 MV (10×10 cm
2
) 
      Depth-dose             Transverse-dose 
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(c)      18 MV (10×10 cm
2
) 
      Depth-dose             Transverse-dose 
 
 
 
 
 
 
Figure 2-3 Monte Carlo calculated dose profiles for a slab phantom geometry with 
decreasing lung slab density (1.25 MV, 6 MV, 18 MV photon sources 10x10 cm
2
 field).  The 
left column corresponds to central-axis depth-dose profiles.  The right column corresponds to 
transverse-dose profiles acquired at the 10 cm depth within the phantom.  
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(a) Depth-dose (1.25 MV, 3×3 cm
2
)    (b) Depth-dose (6 MV, 3×3cm
2
) 
 
 
 
(c) Depth-dose (18 MV, 3×3 cm
2
) 
 
 
 
 
 
 
 
 
Figure 2-4 Monte Carlo calculated central-axis depth-dose profiles for a slab phantom geometry 
with decreasing lung slab density (1.25 MV, 6 MV, 18 MV photon sources 3x3 cm
2
 field). 
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2.3.2 Quantifying electron disequilibrium: relative depth-dose 
factors 
The clinical conditions that create LED are dependent upon beam energy (E), field size 
(FS), and lung density (ρlung).  To quantify the variations in central-axis depth-dose for 
the full range of treatment conditions we used the percent depth-dose value in lung, 
   (          ), acquired at a depth of 10 cm.  We then defined a ratio, the relative 
depth-dose factor (RDDF), to describe the extent of LED:  
      
   (         )
   (                ⁄  
      (2.1) 
For RDDF ≥ 1, electron equilibrium is maintained at the central-axis, and RDDF < 1 
represents conditions that disrupt equilibrium.   The choice of normalization to water was 
based on two key factors: assured electron equilibrium and an often-used calibration 
condition.  For example, from Fig.s 2-3 (b) and 2-4 (b) we can calculate PDD(6 MV, 
10x10cm
2
, 1.0g/cm
3
) and PDD(6 MV, 3x3cm
2
, 0.001g/cm
3
) to be 78% and 12%, 
respectively.  Taking the ratio of these values produces an RDDF (6 MV, 3x3cm
2
, 
0.001g/cm
3
) of 0.15.  Using RDDF, we can estimate the severity of LED and the amount 
of central-axis depth-dose reduction within lung tissue as a result of selecting a specific 
combination of radiotherapy parameters. 
 Figures 2-5 (a), (b), and (c) map iso-contour RDDF values for some selected 
energies: Co-60, 6, and 18 MV.  In Fig. 2-5 (a), regions of severe LED (RDDF ≤ 0.7) 
occur primarily for ultra-low lung densities (< 0.1g/cm
3
) and field sizes less than 5x5cm
2
.  
In Fig. 2-5 (b), the regions of LED begin to spread out, and low RDDF values occur for 
larger field sizes (FS ≤ 10x10cm2) and higher lung densities (ρlung < 0.5 g/cm
3
).  As a 
result of using 18 MV photon energies, the iso-contour lines expand the most in Fig. 2-5 
(c), and LED can even occur in adipose-like tissues (0.7 g/cm
3 < ρlung < 1.0 g/cm
3
) and the 
largest field sizes (FS ≤ 15x15cm2).  Finally, the RDDF metric showed that lung density 
and field size are inversely related, and severe LED can be established for small field 
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sizes and low lung densities.  This is expected since the lateral range of electrons is 
density-dependent and defines the “access” to the field edge. 
(a) RDDF ratios for 1.25 MV photon energy 
 
 
 
 
 
 
 
 
(b) RDDF ratios for 6 MV photon energy 
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(c) RDDF ratios for 18 MV photon energy 
 
 
 
 
 
 
 
 
 Each point in Fig. 2-6 displays the combination of treatment parameters that 
established RDDFs approximately equal to 0.95, or 95% electron equilibrium. This map 
was created by linearly interpolating the two lung densities that produce RDDF values 
just above and below 0.95.  For example, from Fig. 2-4 (b) RDDF (6 MV, 3x3cm
2
, 
0.3g/cm
3
) and RDDF (6 MV, 3x3cm
2
, 0.2g/cm
3
) are 0.98 and 0.93, respectively.  Thus, a 
lung density of 0.25g/cm
3
 would produce a RDDF value of 0.95 for a 6 MV, 3x3cm
2 
photon source.  In Fig. 2-6, regions below each curve (pushing to the bottom left) 
represent the treatment conditions necessary to cause LED with a single field. 
 
 
 
Figure 2-5 iso-contour lines displaying RDDF ratios for various combinations of field 
size, lung density, and beam energies (1.25 MV, 6 MV, 18 MV). Oscillations in 
contour lines are due to interpolation limitations over a sparsely populated matrix (5 
field sizes by 12 densities). 
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2.3.3 Monte Carlo simulations of slab phantoms; with small tumour 
insert 
Figure 2-7 shows depth-dose profiles of the lung slab phantom (including a 3x3x3 cm
3
 
tumour) for 6 and 18 MV photon fields (5×5 cm
2
), and variable lung densities.   Despite 
the expected “build-up” effect of the tumour insert, LED still occurred and caused a 
reduction of dose within the lung tissue, and variable dose level within the tumour 
phantom.  In Fig 2-7 (a), dose to the proximal and distal tumour surfaces (depths = 8.5 
and 11.5cm) were reduced by 11% and 15% with respect to the water density calculation 
for severe LED (lung density = 0.001g/cm
3
; RDDF = 0.3).  On the contrary, the dose at 
the tumour center (depth = 10cm) was enhanced by 8% with respect to the water density 
calculation.  A comparable simulation is shown in Fig. 2-7 (b), which used an 18 MV 
(5x5cm
2
) photon field for dose calculation. Similarly, dose to the proximal and distal 
tumour surfaces were reduced by 24% and 16%.  Dose in the tumour center was 
minimally enhanced by 2% with regard to the water density calculation.  
 
 
 
Figure 2-6 95% electron equilibrium curves showing the conditions required to cause 
lateral electron disequilibrium in a lung phantom using single MV photon fields of 
various energies and field size.  LED regions occur below each line. 
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(a) Depth-dose 6MV (5x5cm
2
)         (b) Depth-dose 18MV (5x5cm
2
)   
 Figure 2-8 shows depth-dose profiles in the lung slab phantom (including a 1x1x1 
cm
3
 tumour) for 6 and 18 MV photon fields (3×3 cm
2
), and variable lung densities.  Note 
that reduced depth-dose values occurs for higher lung densities (compared to Fig. 2-7), 
which was due to a smaller field size.  Fig. 2-8 is similar to Fig. 2-7 except the depth-
dose reduction within the tumour was more severe.  For instance, in Fig 2-8 (a) and (b), 
the dose in the tumour center with lung density of 0.001 g/cm
3 
(RDDF ≈ 0.2) was 
reduced by 10% and 20% compared to the calculated dose in an all water phantom. As 
well, the proximal and distal surfaces of the tumour were both greatly under-dosed in Fig. 
2-8 (a) and (b). 
 
 
 
 
Figure 2-7 Monte Carlo calculated central-axis depth-dose profiles for the lung slab 
phantom geometry (including a 3x3x3 cm
3
 tumour) with decreasing lung slab density. 
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(a) Depth-dose 6MV (3x3cm
2
)   (b) Depth-dose 18MV (3x3cm
2
) 
 For both Fig.s 2-7 and 2-8, reductions in dose to the proximal and distal surfaces 
of the tumour were due to LED in up-stream and down-stream lung tissue.  Elevated 
central tumour dose resulted from reduced photon attenuation in lung.  Low lung density 
up-stream from the tumour reduced attenuation of the photon field, which conserved 
photon fluence for interaction with the tumour volume.  Most importantly, note that 
central tumour dose depends on the beam energy and tumour size in addition to LED 
conditions. Higher energy photon fields require more water depth to reach full build-up 
conditions (i.e. dmax in water).  In Fig. 2-8 (b), under conditions of LED, complete 
rebuild-up is not achieved as an 18 MV beam requires approximately 3.5 cm of water to 
reach maximum dose in water (i.e. dmax).   The tumour was only 1 cm in thickness, which 
was insufficient to attain full build-up conditions. 
 
Figure 2-8 Monte Carlo calculated central-axis depth-dose profiles for the lung slab phantom 
geometry (including a 1x1x1 cm
3
 tumour) with decreasing lung slab density. 
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2.4 Discussion 
2.4.1 Dose calculations within lung tissue: quantifying electron 
disequilibrium 
Figures 2-3 and 2-4 display depth-dose profiles acquired from the lung phantom with no 
tumour insert for various irradiation and tissue density parameters.  These figures were 
chosen as they represent the lower, middle, and upper bounds of all possible 
combinations of beam energy, field size, and lung density.  Similar results were obtained 
for other simulations using other combination of parameters.  In general, for a given 
beam energy and field size, dose within lung tissue increased for reduced lung density if 
equilibrium conditions prevail.  This trend continued until the onset of LED, whereby a 
drastic reduction in lung depth-dose occurred. This effect has been observed and studied 
previously [10, 39, 11, 38, 25, 23, 19, 20, 24, 27], but the interplay of beam energy, field 
size, and lung density has not been fully explored, especially in the context of lung SBRT 
and IMRT. 
  Clinics wishing to perform SBRT of lung cancer patients can use Figs. 2-5 and 2-
6 for considering the risk of LED.  For instance, from Fig. 2-5 it is evident that severe 
LED can be avoided by choosing a low energy beam (< 6 MV) and medium field sizes (> 
5x5 cm
2
) for radiation therapy of lung cancer patients.  However, if a small field (< 1x1 
cm
2
) or low lung density (< 0.1g/cm
3
) is encountered, the deleterious effects of LED are 
unavoidable.  The RDDF values reported in Fig. 2-5 can also impact the choice of dose 
algorithm.  For clinics using dose algorithms that do not account for electron scatter (i.e. 
category 1), we suggest using a combination of treatment parameters that force RDDF   
1.  Otherwise, if the conditions for LED are satisfied, there is a serious risk of producing 
erroneous dose calculations and distributions upon which prescriptions are based.  Figure 
2-6 can be used as an aid for clinicians to select radiation therapy parameters that avoid 
the dose effects of LED, particularly when the accuracy of the dose algorithm is in 
question.   
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2.4.2 Effect of electron disequilibrium on lung tumour dose  
 Of the studies relevant to SBRT of lung cancer patients [26, 20, 22, 21, 40, 11, 41, 
8], few have used MC simulation to study the effect of LED on lung tumour dose.  Most 
studies assume that the dose algorithm can produce accurate calculations within 
heterogeneous tissues, and do not explore the space of possible irradiation parameters.  
Since LED is an effect that is interdependent on beam energy, field size, and lung 
density, our study spanned a wide scope of combinations of these parameters. 
 Our work indicates that the dose distribution located within the tumour is highly 
variable when LED occurs, which may greatly influence fulfillment of the dose 
prescription.  Under-dosage occurred at both the distal and proximal tumour surfaces for 
the conditions of LED. Most importantly, the dose at the tumour center depends on beam 
energy and tumour size.  The beam energy should be chosen such that the tumour 
diameter is larger than the required depth to longitudinal equilibrium (e.g. dmax ~ 2 cm for 
6 MV).  Otherwise, if LED occurs, there is a high risk of severely under-dosing the 
tumour (see Fig. 2-8 (b)) if the dose prescription does not account for disequilibrium.   In 
addition, cold spots can occur near beam edges. 
 Lastly, the primary goal of this work was to quantify the radiation therapy 
parameters that fundamentally cause LED.  To this end, we investigated single fields of 
radiation and homogeneous phantoms to isolate the LED effect (note, within the spatial 
resolution of MC runs, microscope and interface dose effects were assumed to occur 
locally, and were not of clinical importance).  However, the extrapolation of these 
findings to clinical scenarios requires further investigation. For example, when planning 
involves multiple fields of radiation and IMRT optimization, any dose deficiencies 
delivered from one field are accounted for by adjusting intensities from other fields [42] 
provided the dose calculation algorithm (i.e. category 2) correctly models LED.  
Comparison of IMRT treatment plans using 6 MV versus 18 MV beam energies for lung 
cancer patients showed marginal differences between calculated dose distributions [43, 
44].  Therefore a future study using reliable MC analysis (e.g. DOSXYZnrc) and multiple 
fields of radiation would be useful to justify the clinical use of the RDDF metric in 
heterogeneous patient lung/geometry. 
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2.4.3 Implications for SBRT clinical protocols and lung cancer 
patients with emphysema 
 In-line with SBRT protocols, the prescription dose should correspond with the 80% iso-
dose line at the tumour edge.  This prescription assumes that electron equilibrium 
conditions will prevail.  Figures 2-7 and 2-8 suggest that the dose distribution at the 
periphery of the tumour (within lung tissue) varies greatly once equilibrium has been 
perturbed.   Selecting a dose algorithm that does not account for electron scatter (i.e. 
category 1) will inaccurately portray the dose distribution within the vicinity of the 
tumour; the predicted and delivered dose distributions will be drastically different [31].  
Further, LED has the effect of increasing the beam penumbra [45] [39] [46], spreading 
out the dose to healthy adjacent lung.  This makes fulfilling the high and low volume 
dose-volume constraints challenging and potentially misleading if the penumbral profile 
is miscalculated [31].  This implies the recommendations based upon clinical trials using 
dose calculations in homogeneous tissue (i.e. assuming a lung density of 1.00 g/cm
3
) may 
lead to uninterpretable clinical outcomes due to uncontrolled dose at the tumour (RTOG 
0236, and 0618).  More recent protocols still recommend the use of either category 1 or 2 
algorithms for delivery of SBRT to lung cancer patients [30].  Given the large changes in 
the dose distribution for LED conditions, we recommend that treatment planning for 
SBRT in lung be based on a minimum of category 2 algorithms and preferably Monte 
Carlo methods described herein. 
 Observing Figs 2-3 through 2-8, the detrimental effects of LED are the most 
common across all field sizes and beam energies for lung densities below 0.1 g/cm
3
.  
These results are relevant for SBRT/IMRT planning of radiotherapy patients afflicted 
with emphysema as well as lung cancer.  Recently, it has been suggested that this cohort 
of patients present a dosimetric challenge as the tumour is poorly covered, and SBRT 
protocols are ill-defined dosimetrically [47].  Some studies suggest that as much as 90% 
of patients with bronchogenic carcinoma also present with chronic obstructive pulmonary 
disease (COPD), a category of lung disease that includes emphysema [48]. Given that 
emphysema is an independent risk factor for lung cancer [49, 50] it is highly likely that 
SBRT/IMRT will be used to treat many lung cancer patients with low lung density 
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caused by emphysema.  It is suggested that future SBRT trials also consider the effects of 
emphysematous lung tissue on the dose distribution. 
 
2.4.4 Electron disequilibrium creates a hyper-sensitive density 
dependent dose distribution  
In the past, it has been suggested that the dose distribution in lung is relatively insensitive 
to changes in lung density, assuming electron equilibrium.  Parker et al. stated that a 5% 
uncertainty in CT derived density resulted in a deviation of 1% in the calculated dose 
within inhomogeneous tissue [51].  Sontag et al. reported similar results by varying the 
lung density of simple inhomogeneous phantom.  Changing the lung density by 10% 
(from 0.5 g/cm
3
 to 0.55 g/cm
3
) dose inaccuracies of 1.6% and 2.3% were reported at 
depths of 9cm and 21cm, respectively [14].  These findings, however, were relevant to 
circumstances involving electron equilibrium. For conditions of LED, these sensitivity 
ratios are no longer valid as demonstrated amply in our study.  Our work suggests that the 
dose distribution in lung is strongly dependent upon lung density once LED occurs.  For 
example, in Fig. 2-4 (b) at a depth of 15 cm, the percent depth-dose for lung slab 
densities of 0.1 g/cm
3
 (i.e. -900 HU) and 0.01 g/cm
3 
(i.e. -990 HU) are 51% and 18%, 
respectively.  These changes represent only a 10% reduction of HU value, but a ten-fold 
reduction in density, and 48% reduction in central-axis dose under conditions of LED.  
Therefore, in the range of ultra-low lung density, the sensitivity of dose calculations to 
variations in lung density is greatly accentuated and these conditions can certainly occur 
for SBRT or IMRT of lung lesions.   This is a concern for SBRT planning using CT-
derived density from new on-line CT technologies (e.g. cone beam CT mounted on a 
linear accelerator [52]).  These CT systems use a broad-beam geometry to scan the 
patient’s anatomy, and are more susceptible to artifacts and miscalibrations [53, 54].  As 
a result, CT-derived density is less accurate and could lead to erroneous computed dose 
distributions in lung tissue.  A study focused on lung dose variations (for conditions of 
LED) due to inaccurate CT-derived density would be useful. 
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2.5 Conclusions 
This study used Monte Carlo simulations to determine the physical conditions that cause 
lateral electron disequilibrium in a lung phantom.  The findings of this work are useful 
for oncologists and physicists wanting to avoid the dosimetric complications associated 
with unexpected LED that is not predicted by some dose algorithms.  We recommend 
that future SBRT clinical trials only be conducted using dose calculating methods that 
account for electron scatter (i.e. Monte Carlo and category 2 algorithms only).  Finally, 
special attention should be given to patients that present with emphysematous lung.  
These patients are much more susceptible to the detrimental effects of LED due to 
extremely low lung density.  
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Chapter 3  
3 Forcing Lateral Electron Disequilibrium to Spare Lung 
Tissue: A novel technique for stereotactic body radiation 
therapy of lung cancer 
This chapter is adapted from the research article, "Forcing Lateral Electron 
Disequilibrium to Spare Lung Tissue: A novel technique for stereotactic body radiation 
therapy of lung cancer", accepted pending revisions, Physics in Medicine and Biology, 
2013, submitted April 16, by Disher B, Hajdok G, Gaede S, Mulligan M, and Battista JJ. 
 
3.1 Introduction 
Non-small-cell lung cancer continues to be a leading cause of cancer related death in 
North America [1].  The number of lung cancer patients being diagnosed with early 
staged disease (i.e. stage I or II) has grown due to the increased availability of computed 
tomography (CT) imaging [2].  For these patients, the preferable treatment option is 
surgical lung resection.  However, comorbidities, such as emphysema and heart disease, 
can make surgery intolerable [3].  An alternative form of treatment for these patients is 
conventional radiation therapy [RT] (delivered in 20-30 fractions), where a homogeneous 
dose is delivered to the target.  Unfortunately, this technique results in poor tumour 
control probabilities (TCP) of 30% to 40% [3], and a five year survival rate of 20% [4].  
A recently developed RT technique, known as stereotactic body radiation therapy 
(SBRT) or stereotactic ablative radiotherapy (SABR), has been shown to improve TCP to 
greater than 90% and survival rates up to 40% at three years [5].  The SBRT technique 
uses image guidance [6, 7] to accurately focus multiple, small megavoltage (MV) 
radiation beams onto a tumour volume, delivering ablative doses (e.g. 54 Gy) in only a 
few treatment fractions (e.g. 1-5 sessions) [8].  In contrast to conventional RT, SBRT 
uses steep dose gradients and heterogeneous dose distributions to keep lung toxicity low 
while delivering ablative levels of dose to the tumour. 
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 Healthy lung tissue can range in density from 0.1 g/cm
3
 to 0.4 g/cm
3
 [9, 10]. In 
contrast, for lung cancer patients also afflicted by emphysema [11], lung densities can be 
lower than 0.1 g/cm
3
 [12].  The dose distribution in low density media is affected by two 
opposing effects: 1) increased primary photon transmission, and 2) amplified secondary 
electron range.  For conditions of charged particle equilibrium, enhanced photon 
transmission (effect 1) dominates the lung dose distribution, which increases the dose 
within lung and tumour (compared to a homogeneous water medium) [13].  In contrast, 
for conditions that disrupt electron equilibrium (effect 2), large reductions of dose within 
lung and tumour tissues are possible [14, 15, 16, 17, 18].  Lateral electron disequilibrium 
(LED) also significantly expands the dose penumbra at the field edge, which may result 
in inadequate target coverage at the field periphery [19, 20].  
 The effects of LED on lung dose are generally poorly accounted for by 
commercial dose calculation algorithms, which oversimplify the secondary electron 
trajectory [16, 21, 17, 22, 23, 24].  For ‘SBRT-like’ treatment conditions in lung tissue, 
poorly modelled LED dose perturbations may not predict the actual delivered dose 
distribution [25] [26].  Historically, to avoid the deleterious effects of LED and algorithm 
deficiencies, previous authors suggested using lower energy photons (< 10MV) and 
larger “equilibrium” field sizes (> 5x5cm2) for RT of lung cancer patients [27, 28, 29, 30, 
19, 31, 32]. 
 For radiotherapeutic conditions that disrupt equilibrium (>4MV photons, field 
sizes < 5x5 cm
2
, lung density <0.4 g/cm
3
), the Monte Carlo (MC) technique [33] is the 
preferred method for determining accurate dose distributions.  In contrast to analytical 
methods [33] [34], MC methods explicitly track electron transport, and have been used to 
benchmark simpler dose calculation algorithms [16, 24, 35, 36, 37, 21, 22, 17].  
Previously, our group used the MC technique to determine the specific combination of 
radiation therapy parameters that result in LED [14].  In a phantom study, a small tumour 
(1x1x1cm
3
) was embedded within lung tissue, and irradiated using a single 18 MV 
(3x3cm
2
) field.  Under conditions of severe LED, lung and tumour depth dose were 
reduced by as much as 80% and 15% (with respect to an all water absorber), respectively.  
These results imply that LED could be exploited to leverage a therapeutic ratio that 
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maximizes the dose within the tumour, while controlling healthy lung dose to acceptable 
levels.  Blomquist, et al. were the first to propose that LED could be used to safely 
increase the dose delivered to lung tumours [38, 39].  They proposed using 50 MV 
radiation fields (e.g. 2), and a traditional dose fractionation scheme (e.g. 30 fractions).  
However, such a technique is not clinically viable. 
 In this work, we propose a novel LED-optimized SBRT (LED-SBRT) treatment 
method, where specific radiotherapeutic parameters are chosen in order to cause extreme 
LED.  This will be demonstrated with the introduction of a new clinical ‘tool’ described 
as LED maps.  Further, using both a lung phantom and patient MC simulation, it will be 
shown that LED-SBRT can be used to enhance the steepness of dose gradients, to 
additionally increase the ablative levels of dose within the tumour, and further reduce the 
dose in normal lung.  The LED-SBRT technique provides an opportunity to optimize the 
desired tumour dose enhancement and/or lung tissue sparing via manipulation of RT 
parameters (beam energy and field size) for a given tumour size.  With LED-SBRT, there 
is an opportunity to increase tumour dose. However, this may be perceived as 
controversial to the community, and a discussion on this topic is provided here-in. 
 
3.2 Methods 
3.2.1 Monte Carlo codes and parameters 
MC simulations were performed using the DOSXYZnrc user code (National Research 
Council of Canada, Ottawa, ON). Simulations were run concurrently using a cluster of 
PC-based 60 independent Intel Xeon central processing units (Intel Corporation, Santa 
Carla, CA). These systems operated at processing speeds of 2.67 or 3.4 GHz, and had a 
combined accessible total RAM of 102 GB.   For lung phantom simulations, electron and 
photon transport parameters (i.e. ECUT and PCUT) were set as ECUT = 0.521 MeV, and 
PCUT = 0.010 MeV. For the lung patient simulation, ECUT was varied between 
0.521MeV, 6MeV, or 18MeV energies, and PCUT = 0.010 MeV. For electron energies 
below ECUT, DOSXYZnrc terminates the history and deposits the electron energy “on 
the spot” [40].  Setting ECUT to the maximal photon energy will result in all liberated 
63 
 
electrons being absorbed locally or at the site of photon interaction.  This is analogous to 
simulating charged particle equilibrium (CPE), and the calculated dose is unaffected by 
electron transport.  By setting ECUT as low as possible [i.e. 0.521 MeV (including rest 
mass energy)] the dose is dependent on electron scattering conditions, and CPE or LED 
maybe observed.  Finally, PRESTA II [41] and EXACT algorithms were selected as the 
electron step and boundary crossing algorithms.  DOSXYZnrc was used to perform all 
dose calculations, and up to 8 × 10
9
 histories were used per simulation to keep statistical 
noise to less than 2% for dose voxels.  The depth-dose profiles displayed in subsequent 
figures were normalized to the dose at maximum depth (i.e. Dmax; per energy and field 
size) in water unless specified otherwise. 
 The suitability of DOSXYZnrc to accurately calculate the dose distribution for 
conditions of extreme LED has been assessed previously by our group [14].  In brief, a 
real water-air-water phantom was created at our centre, which was also virtually 
modelled within the DOSXYZnrc software.  We observed better than 2% agreement 
comparing measurement against MC dose calculation within water regions.  Similarly in 
air regions, where severe LED persists, measurement and calculation agreed within 3%.  
An analogous MC validation study was performed by Chow, et al., 2009, which produced 
results comparable to our own [21]. 
 
3.2.2 Cylindrical lung phantom simulations 
MicroView Analysis+ software V2.2 (GE Healthcare®, Waukesha, WI) was used to 
create a virtual CT image of a cylindrical lung phantom [see Fig. 3-1 a) and b)].  This 
phantom was used to demonstrate the potential tumour/lung dose effects of LED-SBRT 
under the assumptions of homogeneous lung density, and in the absence of lung breathing 
motion.  The height and diameter of the phantom were 25 cm.  At the phantom centre, a 1 
cm solid water cylindrical tumour (density = 1 g/cm
3
) was embedded into an inner 
cylindrical lung shell (density = 0.25 g/cm
3
), which had annuli extending from r = 0.5 to 
7.5 cm, and a height equal to 25 cm (z = -12.5 cm to 12.5 cm).  The outer-most “chest 
wall” shell consisted of water (density = 1 g/cm3) annuli traversing r = 7.5 cm to 12.5 cm 
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in addition to having a height equal to 25 cm (z = -12.5cm to 12.5cm). The CTCREATE 
module [40] was used to convert the CT image of the phantom into a DOSXYZnrc-
compatible form (i.e. an egsphant file) with 1 x 1 x 3 mm
3 
sized voxels.   
 Source type ‘0’ (i.e. parallel rectangular beam) was selected within the input 
settings, and 6 MV and 18 MV photon spectra [42] were applied.  For each energy, 
square field sizes of 1x1 cm
2
, 3x3 cm
2
, and 5x5 cm
2
 were used to collimate the photon 
field.  To simulate a 180
o
 SBRT arc, a single field dose distribution was calculated at 0
o
.  
This dose distribution was then exported into Matlab V. R2012a (The MathWorks Inc., 
Natick, MA) software where it was rotated and summed incrementally by 1
o
 segments 
until the total cumulative 180
o
 arc dose was complete. This approach was valid as the 
phantom is symmetric and homogeneous in composition. 
(a) The cylindrical phantom   (b) Transverse view showing the x-y plane  
            intersecting at the tumour (z = 0). 
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       (c) Transverse view of the lung patient CT  
 
 
 
 
 
 
3.2.3 Lung patient simulations 
A CT image of a SBRT lung cancer patient was acquired using a 16-slice helical CT 
simulator unit (Brilliance Big Bore CT, Philips Medical Systems, USA).  Image 
acquisition parameters were set to: 120 kVp, 400 mAs/slice, 0.5 sec rotation time, and the 
pitch varied in accordance with the patient’s breathing cycle.  CT images were 
reconstructed at 10 different points within the breathing cycle, and a time-averaged 4-
dimensional CT (4DCT) was created for use in this study.  The 4DCT image set was 
reconstructed using a slice thickness of 3 mm, onto a 512 x 512 pixel matrix over a field-
of-view of 45 cm [see Fig. 3-1 (c)].  CTCREATE was again used to convert the lung 
patient CT data to the “egsphant” format with a voxel resolution of approximately equal 
to 1 x 1 x 3 mm
3
. 
Figure 3-1 (a) shows a schematic diagram (not to scale) of the cylindrical phantom 
used in this work.  Fig. 3-1 (b) displays the transverse view of the phantom at the 
tumour center. The tumour was modelled by a small water cylinder with a height 
and diameter of 1cm.  Fig. 3-1 (c) shows the transverse view of the lung patient 
including tumour (spherical diameter ~ 1 cm).  To demonstrate the lung sparing 
effect of lateral electron disequilibrium, 6 MV or 18 MV beam energies (various 
field sizes) were focused onto the tumour center in both phantom and patient Monte 
Carlo simulations. 
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 As the lung cancer patient was originally treated with the SBRT technique at our 
centre, lung and tumour contours were generated by a radiation oncologist.  The patient’s 
lung tumour was spherically shaped with a diameter of ~ 1 cm.  Ten separate gross 
tumour volume (GTV) contours were created to encompass the extent of the tumour 
motion for each phase of the patient’s breathing cycle (tumour motion occurred primarily 
along the superior-inferior direction).  The internal gross tumour volume (IGTV) was 
created by taking the union of each GTV in 3-dimensions over the entire breathing cycle.   
The planning target volume (PTV) included the IGTV plus a 5mm isotropic expansion to 
account for treatment uncertainties (i.e. patient setup).  The PTV was ovoid shaped with a 
length of ~3 cm along the superior-to-inferior direction, and a diameter of ~1.5 cm in the 
transverse plane.  As well, a healthy lung volume was determined by considering the 
patient’s entire lung volume less the IGTV.  Dose calculations were performed within 
DOSXYZnrc by aiming either 6 MV or 18 MV photon beams [42] onto the patient’s 
tumour centre.  Source type ‘1’ was selected within the input settings for the patient MC 
simulations. This allowed for angular rotation of the photon source about the patient’s 
superior-inferior axis.  The field size was chosen to be as small as possible while still 
providing adequate longitudinal coverage to the PTV.  Variations in field size were 
therefore only possible along the transverse axis.   
 Since LED is more prevalent at higher beam energies we varied the square field 
size for the 18 MV energy only (3x3 cm
2
, 3x2.5 cm
2
, 3x2 cm
2
, and 3x1 cm
2
).  Clinical 
SBRT lung recommendations [Radiation Therapy Oncology Group (RTOG) trials 0236, 
0618, 1021, 0813, and 0915] suggest using beam energies less than 10MV.  Thus, the 6 
MV (3x3cm
2
) simulation was selected to represent the clinical control for comparison.  
For each combination of beam energy and field size, 36 equally spaced and weighted 
fields were used to span a range of 360
o
 to simulate an SBRT arc treatment.  All arc dose 
distributions were normalized such that 95% or more of the PTV received at least 54Gy 
(i.e. the D95 dose prescription requirement).  Finally, the normalized dose distributions, 
contours, and CT data were analyzed using the Computational Environment for 
Radiotherapy Research (CERR) software run within Matlab. [43] 
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3.2.4 Lateral electron disequilibrium maps   
An excellent review of the relevant physics involving MV photons and low density media 
has been provided by The American Associate of Physicists in Medicine (AAPM) Report 
Number 85[32].  In short, energy deposition in human tissues (due to impinging photon 
fluence) can be broken into two sequential components: 1) photon interactions that impart 
kinetic energy to electrons, and 2) electrons depositing energy locally through ionization 
and excitation events along their path. From step 1), we define KERMA as the kinetic 
energy released to electrons per unit mass; from step 2), KERMAC is the kinetic energy 
released and absorbed locally along electron paths per unit mass (KERMAC is equal to 
KERMA less radiative Bremsstrahlung events).  Charged particle equilibrium (CPE) 
exists when there is a balance between the electron energy fluence entering and leaving a 
small volume of interest.  For CPE conditions, the absorbed dose (D) is equal to 
KERMAC (Kc): 
                (3.1) 
However, true CPE is impossible in a clinical radiotherapy beam because photon beam 
divergence and attenuation perturb the “steady state” flux of electrons [44].  Conversely, 
transient charged particle equilibrium (TCPE) is achievable along the central-axis of a 
field of radiation, so long as the depth exceeds the maximum forward electron range, and 
the field radius surpasses the lateral electron range (establishing lateral electron 
equilibrium).  Under TCPE the dose scales proportionally to KERMAC such that their 
ratio is always greater than unity at depths greater than Dmax: 
 
  
               (3.2) 
The primary goal of this paper was to select appropriate radiotherapeutic parameters that 
force lateral electron disequilibrium within lung tissue such that the ratio in equation (3.2) 
is advantageously less than unity: 
 
  
                       (3.3) 
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As such, it may be possible to spare lung tissue from the effects of radiation exposure 
along beam path directions.  Finally, by considering D/KC, we can determine how 
electron trajectories affect the overall dose distribution and have an index of 
disequilibrium.  Visualizations of this ratio can provide a map of lateral electron 
disequilibrium. 
3.3 Results 
3.3.1 Cylindrical Lung Phantom Simulations 
 Figure 3-2 (a) displays a transverse slice of the cylindrical lung phantom at the 
tumour centre.  The red line depicts where single field dose profiles were extracted.  Fig. 
3-2 (b) shows the central-axis depth-dose profile for a 6 MV beam energy collimated to 
1x1 cm
2
, 3x3 cm
2
 or 5x5 cm
2
 field sizes.  For the 6 MV (5x5 cm
2
) profile, the dose within 
the downstream lung, tumour and water shell was maintained due to reduced photon 
attenuation through the low density lung tissue.  On the contrary, the 6 MV (3x3 cm
2
) and 
6 MV (1x1 cm
2
) dose profiles both showed reduced dose levels within the lung shell as 
equilibrium was lost for this selection of RT parameters.  As a general rule, the lateral 
path-length of free electrons is approximately 1/3 to 1/2 the longitudinal electron range 
[18].  In water, for a 6 MV photon source (Dmax = 1.5cm), the lateral range of electrons 
was between 0.5 cm and 0.75 cm.  However, since the electron path-length scales 
inversely with density, the lateral range increased from 2 cm up to 3 cm in lung tissue. As 
such, the lateral electron trajectory could reach the lateral beam radius (1.5 cm). These 
electrons scattered beyond the field edge, were not replaced, which reduced the central-
axis depth-dose profile within lung tissues [18, 21, 32].  Also note that LED was more 
severe using the 1x1cm
2
 field size, which produced the lowest dose levels within lung 
tissue.  Despite the ‘build-down’ of dose within lung tissues, there was still a ‘build-up’ 
of dose within the tumour.   
 Figure 3-2 (c) shows comparable results for the 18 MV beam.  Also notice that 
Dmax appeared to be slightly more shallow for the 18 MV (1x1cm
2
) result in comparison 
to the other profiles.  As the field size was decreased below the lateral electron range in 
water, Compton electrons liberated from the field periphery no longer reach the central-
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axis at depths below the site of photon interaction, which shifted Dmax back toward the 
phantom surface [45]. 
(a) A transverse view of the phantom (at the tumour center) displaying the location of the 
depth dose profile (i.e. the red line), and the single field of radiation. 
 
 
 
 
 
 
 
 
 
(b) Single field depth-dose profiles acquired from 6 MV simulations. 
 
 
 
(c) Single field depth-dose profiles acquired from 18 MV simulations. 
  
 
 
 
 
 
70 
 
(c) Single field depth-dose profiles acquired from 18 MV simulations. 
 
 
 
Figure 3-3 (a) displays a transverse slice of the cylindrical lung phantom at the tumour 
centre.  The red line depicts where 180
o
 arc dose profiles were extracted.  Figs. 3-3 (b) 
and (c) display arc depth-dose profiles for 6 MV and 18 MV beam energies for various 
field sizes (1x1 cm
2
, 3x3 cm
2
 or 5x5 cm
2
).  Results were normalized such that 100% 
depth dose falls on the tumour edge.  In this way, changes in lung and tumour dose can be 
better visualized for equal dose coverage of the tumour.  In both figures, shrinking the 
field size exaggerated LED, which greatly spared the lung tissue.  For example, in Fig. 3-
3 (c), the lung dose at depth = 10.5 cm decreased from 92% to 62% or 23% for the 5x5 
cm
2
, 3x3 cm
2
 or 1x1 cm
2 
fields (18 MV energy).  In both Figs. 3-3 (b) and (c), despite 
reduced lung dose levels, the maximal tumour dose was greater than 125% for the 1x1 
Figure 3-2 (a) shows a transverse view of the cylindrical phantom (at the tumour center) including 
the line profile where single field depth-dose profiles were acquired for a 6 MV [Fig. 3-2 (b)] and 18 
MV [Fig. 3-2 (c)] beam energy. Note that lateral electron disequilibrium is more dominate at higher 
beam energies and smaller field sizes. 
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cm
2 
field size (6 and 18 MV energy).  These dosimetric effects are due to the enhanced 
dose gradients present at the lung/tumour interface, which occur when LED is severe.   
(a) A transverse view of the phantom (at the tumour center) displaying the location of the 
depth-dose profile (i.e. the red line), and the 180
o
 arc of radiation. 
 
 
 
 
 
 
 
 
 
(b) 180
o
 arc depth-dose profiles acquired from 6 MV simulations. 
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(c) 180
o
 arc-depth dose profiles acquired from 18 MV simulations. 
 
3.3.2 Lung patient simulations 
Figure 3-4 (a) shows a transverse view of a lung patient at the tumour centre.  The red 
line indicates where arc depth-dose comparisons were made in Fig. 3-4 (d).  Figs. 3-4 (b) 
and (c) display the clinical standard [6 MV (3x3 cm
2
)] and LED-optimized [18 MV (3x1 
cm
2
)] 360
o
 arc dose distributions overlaid on the lung patient anatomy.  Comparing Fig. 
3-4 (b) to (c), the reduction in field size along the transverse plane is easily visualized.  
Further, the high dose and steep dose gradient regions are better confined to the vicinity 
Figure 3-3 (a) shows a transverse view of the cylindrical phantom (at the tumour center) including 
the line profile where arc depth dose profiles were acquired for 6 MV [Fig. 3-3 (b)] and 18 MV [Fig. 
3-3 (c)] beam energies. Note that lateral electron disequilibrium, established for 18 MV (1x1 cm
2
) 
energies, reduced lung dose by as much as 70%. 
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of tumour in Fig 3-4 (c).  Also notice the low to medium dose region within the right lung 
(light green and yellow colours) that encompasses a smaller area in Fig. 3-4 (c).  Figure 
3-4 (d) compares the 6 MV (3x3 cm
2
) arc to the various sized arcs at 18 MV energy.  The 
magnitude of lung sparing and tumour dose increase was related to the extent of LED.  
For example, the lung dose at depth = 12 cm was 22 Gy, 24 Gy, 26 Gy, and 29 Gy for the 
18 MV 3x1 cm
2
, 3x2 cm
2
, 3x2.5 cm
2
, or 3x3 cm
2
 compared to 28 Gy for the 6 MV (3x3 
cm
2
) plan.  The greatest lung sparing occurred using the highest energy beam collimated 
to the smallest field size.  Also, tumour dose was increased to a greater extent for arc 
plans where LED was more severe.  Table 3-1 displays the maximal, mean, and 
minimum dose metrics for the PTV across the various arc plans.  For example, comparing 
the LED-optimized plan [18 MV (3x1 cm
2
)] to the conventional arc [6 MV (3x3 cm
2
)], 
the maximal, mean, and minimal dose were increased by 80 Gy, 11 Gy, and 3 Gy, 
respectively.  These results indicate that LED can be exploited to create steep dose 
gradients, which increase and localize high dose levels within the PTV, while 
maintaining or improving the peripheral lung dose. 
PTV Dose 
Metrics 
360
o
 Arc Plans 
 6 MV 
3x3cm
2
 
18 MV 
3x1cm
2
 
18 MV 
3x2cm
2
 
18 MV 
3x2.5cm
2
 
18 MV 
3x3cm
2
 
Mean Dose (Gy) 70 81 72 70 70 
      
Max. Dose (Gy) 89 169 105 96 91 
      
Min. Dose (Gy) 44 47 45 44 44 
Table 3-1 compares the mean, maximum, and minimum dose values within the planning 
target volume (PTV) for the various arc plans.  The LED-optimized plan [18 MV (3x1 
cm
2
)] produced the highest dose values for all three PTV dose metrics. 
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(a) Transverse view (b) Clinical standard 360
o
 arc (6MV 3x3cm
2
) (c) LED-optimized 360
o
 arc (18MV3x1cm
2
)                                                                  
 
 
 
 
 
      (d) 360
o
 arc depth dose profiles  
 
 
 
 
 
 
 
 
 
Figure 3-4 (a) shows a transverse view of the lung patient including the line profile where arc depth-dose profiles were acquired.  Fig. 3-4 (b) and (c) display a 
transverse view of the 6 MV (3x3cm
2
) and 18 MV (3x1cm
2
) 360
o
 arc dose distributions in the vicinity of the tumour.  Fig. 3-4 (d) presents various 360
o
 arc 
depth-dose profiles.  The LED-optimized arc [i.e. 18 MV (3x1cm
2)] produced a ‘hot spot’ in the tumour center that was approximately two times the value 
observed using the clinical standard arc [i.e. 6 MV (3x3cm
2
)].  Despite increased tumour dose levels, the LED-optimized plan produced the lowest lung dose 
distribution.  Note, the colour bar is relevant to Fig.s 3-4 (b) and (c) only. 
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 Figure 3-5 (a) shows a coronal view of the lung patient at the tumour centre.  The 
red line indicates where arc depth-dose comparisons were made in Fig. 3-5 (d).  Figs. 3-5 
(b) and (c) display the clinical standard [6 MV (3x3 cm
2
)] and LED-optimized [18 MV 
(3x1 cm
2
)] 360
o
 arc dose distributions overlaid on the lung patient anatomy.  As the 
PTV’s longest axis aligned with the superior-to-inferior direction, it was not possible to 
reduce the field size in the coronal plane while maintaining adequate PTV coverage.  
Also, comparing Fig. 3-5 (b) and (c), the dose penumbra was wider for the LED-
optimized plan, an effect due to the increased lateral electron range for higher energy 
electrons.  This is also evident from observing Fig. 3-5 (d) as the dose profile just beyond 
the PTV border is the highest for the LED-optimized plan.  As in Fig. 3-4 (d), the coronal 
dose profile within the PTV was largest for the 18 MV (3x1 cm
2
) arc, followed by the 18 
MV (3x2 cm
2
), 18 MV (3x2.5 cm
2
), 18 MV (3x3 cm
2
), and 6 MV (3x3 cm
2
) plans (see 
Table 3-1 for specific dose values within the PTV). 
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(a) Coronal view  (b) Clinical standard 360
o
 arc (6MV 3x3cm
2
)  (c) LED-optimized 360
o
 arc (18MV3x1cm
2
) 
  
  
  
         
 
                 (d) 360
o
 arc depth dose profiles  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5 (a) shows a coronal view of the lung patient including the line profile where arc depth-dose profiles were acquired.  Fig.s 3-5 (b) and (c) display a 
coronal view of the 6 MV (3x3cm
2
) and 18 MV (3x1cm
2
) 360
o
 arc dose distributions in the vicinity of the tumour.  Fig. 5 (d) presents various 360
o
 arc depth 
dose profiles.  Comparing the LED-optimized arc [i.e. 18 MV (3x1cm
2
)] to the clinical standard arc [i.e. 6 MV (3x3cm
2
)], the planning target volume (PTV) 
received more dose along the superior-inferior axis.  Note, the colour bar is relevant to Fig.s 3-5 (b) and (c) only. 
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 Figure 3-6 compares the dose volume histograms (DVH) for the PTV for the 18 
MV (3x1 cm
2
), 18 MV (3x2 cm
2
), 18 MV (3x2.5 cm
2
), 18 MV (3x3 cm
2
), and 6 MV (3x3 
cm
2
) arc plans.  All plans met the prescription requirement such that 95% or more of the 
PTV received at least 54 Gy (i.e. D95).  However, plans that exploited the LED 
phenomenon produced a significant ‘hot spot’ within the PTV centre (see maximum dose 
in Table 3-1).  
 
Figure 3-6 displays the dose volume histograms comparing arc dose for the planning 
target volume (PTV) using either the 6 MV 3x3cm
2 
, 18 MV 3x3cm
2
, 18 MV 3x2.5cm
2
, 
18 MV 3x2cm
2
, or 18 MV 3x1cm
2
 plans.  All plans met the D95 prescription 
requirement.  In addition, the LED-optimized plan (i.e 18 MV 3x1cm
2
)  produced a 
‘hotspot’ of approximately 170Gy at the tumour center( ~ 3 times the prescription dose of 
54Gy).  
 Figure 3-7 displays DVHs with regard to the healthy lung volume and the various 
arc plans.  Upon first inspection of Fig. 3-7 (a), there appeared to be very little difference 
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between the lung DVHs across all plans.  However, Fig. 3-7 (b) shows an expanded view 
of the DHVs, and in general, the lung DVHs increase in order starting from the 18 
MV (3x1 cm
2
) plan, up to 18 MV (3x2 cm
2
), 18 MV (3x2.5 cm
2
), 6 MV (3x3 cm
2
), and 
18 MV (3x3 cm
2
) plans.  Note there were some deviations away from this trend in the 
vicinity of the V5 region where the 6 MV (3x3 cm
2
) and 18 MV (3x1 cm
2
) arcs were 
comparable, but lower than for the remaining plans.  The specific variations in the V5, 
V20, and mean lung dose are provided in Table 3-2.  Of noticeable importance is the 
sensitivity of these lung dose metrics to changes in the radiotherapeutic parameters.  For 
example, by increasing the 18 MV transverse field size from 1 cm to 3 cm, we observed 
changes in the mean lung dose, V20, and V5 of 0.8 Gy, 1.8%, and 6%, respectively.  
Finally, comparing the lung dose metrics of the LED-optimized arc [18 MV (3x1 cm
2
)] to 
our clinical standard [6 MV (3x3 cm
2
)], the V20 and mean lung dose were lower while 
the V5 remained the same.  Indeed, careful attention must be paid to these parameters if 
we are to improve or maintain the normal lung dose distribution, while intentionally 
manipulating the extent of LED.  
Lung 
Metrics 
360
o
 Arc Plans 
 6 MV 
3x3cm
2
 
18 MV 
3x1cm
2
 
18 MV 
3x2cm
2
 
18 MV 
3x2.5cm
2
 
18 MV 
3x3cm
2
 
Mean Dose 3.7Gy 3.4Gy 3.6Gy 3.9Gy 4.2Gy 
      
V20 4.3% 3.2% 3.6% 4.1% 5.0% 
      
V5 18% 18% 20% 22% 24% 
Table 3-2 compares three lung dose metrics for the various arc plans.  Mean Dose = 
average dose from the entire volume of healthy lung tissue (lung volume less the internal 
gross tumour volume).  V20 = the percent of the healthy lung volume receiving 20Gy or 
more.  V5 = the percent of the healthy lung volume receiving 5Gy or more. Both the V20 
and Mean Dose metrics are lowest for the LED-optimized, 18 MV (3x1 cm
2
), plan. 
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(a) Dose volume histogram for healthy lung 
 
 
 
 
 
 
 
 
 
(b) Expanded view of dose volume histogram for healthy lung 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7 (a) displays the dose volume histograms comparing arc dose for the healthy lung 
volume (lung volume less the internal gross tumour volume) using either the 6 MV 3x3cm
2 
, 18 MV 
3x3cm
2
, 18 MV 3x2.5cm
2
, 18 MV 3x2cm
2
, or 18 MV 3x1cm
2
 plans.  Fig. 3-7 (b) displays the same 
information, but expands on the V5 and V20 regions (i.e. the volume of healthy lung receiving 5Gy 
or 20Gy or more).  Note the lung DVH related to the 18 MV 3x1cm
2
 plan received the least dose in 
the V20 region.  See Table 2 for a comparison of lung dose metrics. 
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3.3.3 Lateral electron disequilibrium maps 
By studying the dose to KERMA ratio we can determine whether the chosen RT 
parameters (i.e. photon energy, field size, and lung density) combine to promote LED 
(dose/KERMA < 1).  As a demonstration, we focused a single 6 MV (10x10 cm
2
) field of 
radiation onto the tumour centre of our test patient, and calculated both the KERMA 
(ECUT = 6 MeV) and dose (ECUT = 0.521 MeV).  We then repeated this process using a 
single field of radiation utilizing the proposed LED-optimized RT parameters [i.e. 18 MV 
(3x1cm
2
)].  Figure 3-8 (a) shows the transverse view of the lung patient with the 6 MV 
(10x10 cm
2
) field demarked in red, and the 18 MV (3x1 cm
2
) field demarked in blue.  In 
Fig. 3-8 (b) the KERMA and dose for the 6 MV (10x10 cm
2
) field are plotted along the 
central-axis of the beam.  Initially, within the patient’s anterior chest wall, the dose is 
well below the KERMA.  However, beyond Dmax the KERMA and dose values converge.  
For shallow depths above Dmax, longitudinal electron disequilibrium exists, which creates 
the characteristic build-up curve within the anterior chest wall.  For depths below Dmax, 
the dose is similar to the KERMA within the chest wall, tumour, and lung tissues.  Since 
the 10x10 cm
2
 field size is large enough to establish lateral electron equilibrium, the 
conditions for TCPE are met, and dose is maintained throughout these tissues.  
 Figure 3-8 (c) shows a similar comparison using the 18 MV (3x1 cm
2
) settings.  
For a 3x1 cm
2
 field size, with the shortest axis aligned along the transverse plane, lateral 
electron equilibrium was not achievable for water density.  Therefore, the dose was less 
than the KERMA over the entire profile. The largest reductions in the dose profile 
occurred within lung tissue, as low densities exaggerated LED and enhanced lung 
sparing.  Also, there was an observed dose ‘rebuild-up’ within the tumour despite the 
lower lung dose.   
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(a) Transverse view of lung patient CT with the single field edges demarked (red and 
blue) 
 
 
(b) Comparison of KERMA and dose for a 6 MV 10x10cm
2 
single field 
 
 
 
 
 
(c) Comparison of KERMA and dose for an 18 MV 3x1cm
2 
single field 
 
 
 
 
 
 
 
 
 
Figure 3-8 (a) shows a transverse view of the lung patient with the 6 MV (10x10cm
2
) and 18 MV (3x1cm
2
) 
field edges demarked in red and blue. Fig.s 3-8 (b) and (c) compare the KERMA (ECUT = 6MeV or 
18MeV) to dose (ECUT = 0.521MeV) along the field central-axis.  In Fig. 3-8 (c), lateral electron 
disequilibrium (LED) causes the KERMA and dose profiles to diverge.  This effect can be exploited to spare 
lung tissue for SBRT of lung cancer.  
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 Figures 3-9 (a) – (e) display a transverse slice of the dose-to-KERMA ratios 
(or LED maps) for the 6 MV (3x3 cm
2
), 18 MV (3x3 cm
2
), 18 MV (3x2.5 cm
2
), 18 MV 
(3x2 cm
2
), and 18 MV (3x1 cm
2
) arc plans.  For increased beam energy and smaller field 
sizes, the ratio was reduced below unity (an indicator of LED).   On the contrary, for 
lower energy and larger field sizes, the ratio approached unity.  For example, the 18 MV 
(3x1 cm
2
) LED map contained many lung regions valued from 0.4 to 0.6, while the 6 
MV (3x3 cm
2
) map displayed values between 0.6 and 1.0. Figure 3-9 (f) shows the lateral 
electron disequilibrium volume histograms (LVH) for the various arc plans.  These 
histograms were created by considering only those lung voxels contained within the beam 
paths (the entire healthy lung volume was not considered in this analysis).  Once again, 
for the volume of lung tissue traversed by the arcs, the lowest dose to KERMA ratios 
were observed for those plans with the highest energy and smallest field size [i.e. 18 MV 
(3x1 cm
2
) or LED-optimized plan].  These findings explain the results shown in Figures 
3-4 through 3-7, and support the hypothesis that the LED phenomenon can be exploited 
to maintain or lower lung dose, while increasing dose levels within the tumour volume.  
Finally, the ripple artifact observed between adjacent fields in Figs. 3-9 (a) - (e), and 
discontinuities present within Fig. 3-9 (g), are due to an under-sampled arc dose 
distribution.  We expect these artifacts to greatly diminish with the addition of more 
overlapping fields to complete a full 360
o
 SBRT arc. 
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(a) 6 MV 3x3cm
2 
LED  (b) 18 MV 3x3cm
2 
LED                       (f) Lateral electron disequilibrium volume histograms 
 
 
(c) 18 MV 3x2.5cm
2 
LED (d) 18 MV 3x2cm
2 
LED  
 
 
  (e) 18 MV 3x1cm
2 
LED map 
 
 
 
 
 
          
Figure 3-9 (a) – (e) displays the ratio of dose to KERMA, which indicates the severity of lateral electron disequilibrium for each arc plan.  As the 
ratio decreases to zero, LED is more prevalent, which spares lung tissue along beam path directions. Fig. 3-9 (f) shows lateral electron 
disequilibrium volume histograms (LVH) acquired from the various arc plans. The LVHs were acquired from the volume of healthy tissue along 
beam path directions only (not the entire healthy lung volume).  The LVH for the 18 MV 3x1cm
2 
demonstrates that LED is most prevalent for this 
choice of beam energy and field size. 
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3.4 Discussion 
3.4.1 LED-SBRT: potential benefits and controversy 
The LED-SBRT technique uses specific combinations of beam energy and field size in 
order to intentionally disrupt charged particle equilibrium in lung tissue, thus forcing 
lateral electron disequilibrium.  In doing so, an extremely steep dose gradient at the 
tumour/lung interface occurs, which can be used to increase dose within the tumour, 
and/or maintain or lower dose in normal lung.  The magnitude of the dose gradient 
spanning these tissues depends on the selected RT and patient parameters (e.g. lung 
density).  Thus, in the planning of LED-SBRT, a physicist must be aware of the dose 
balance between adjacent tumour and lung tissues, and carefully design treatment in 
accordance with SBRT protocols [46]. 
 Using LED-SBRT for our sample patient, we were able to increase the minimum, 
mean, and maximum dose found within the PTV, while maintaining PTV dose coverage 
and lung dose. The hypothetical benefit of increasing tumour dose for early-stage lung 
cancer may include: higher tumour control, lower probability of local tumour recurrence, 
improved radiobiological effects (tumour hypoxia), and hence better overall survival 
rates. Simultaneously, the benefit associated with a lower lung dose can potentially 
reduce side-effects, such as radiation pneumonitis and fibrosis.  However, the therapeutic 
benefits associated with LED-SBRT will be limited in clinical practice, depending upon 
the location of the tumour within lung.  For example, in our sample patient, the tumour 
was surrounded by sufficient lung tissue to force LED.  In contrast, tumours located 
adjacent to chest wall or mediastinum will become difficult to intentionally establish 
LED, due to surrounding water equivalent material. Nonetheless, under the latter 
scenario, our technique may still be beneficial if some LED can be produced, thereby 
creating a steeper dose gradient to spare adjacent critical structures (e.g. ribs, bronchus, 
trachea, and esophagus).  
 The idea of further increasing tumour dose using LED-SBRT may seem 
controversial. Currently, SBRT treatment plans are normalized anywhere between the 
60% to 90% isodose lines, which can create hotspots on the order of 111% up to a 
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maximum of 167% [47]. While other SBRT protocols do not specifically limit the 
maximum dose within the PTV [25]. In a recent publication, van Baardwijk et al. argued 
against this SBRT prescription philosophy [48].  They completed a systematic review of 
radiation doses required to eradicate early-stage lung cancer, where they hypothesized 
that a lower and more uniform dose to the entire PTV may be sufficient to achieve local 
tumour control and reduce high-grade toxicity.  However, conclusions from their study 
were focused on centrally located tumours only.  In clinical practice, alternative 
fractionation schedules (e.g. 60 Gy in 8 fractions) are generally used for these tumours to 
reduce surrounding normal tissue toxicity. Clearly, further investigation is required to 
determine whether additional increases in SBRT tumour dose will lead to further 
increases in tumour control (current ablative doses may be sufficient to achieve the 
desired tumour control probability without tumour overkill). 
 
3.4.2 LED-SBRT and tumour size 
In this study, we also varied the size of the tumour from 0.25 cm up to 5 cm within the 
cylindrical lung phantom.  This was done in order to assess the dosimetric effect of 
tumour size on LED-SBRT derived dose distributions.  We classified the tumour size as 
small (< 1cm), medium (1 to 3 cm), or large (> 3 cm) in accordance with clinical 
observation of early-staged lung cancers.  For small-sized tumours, a minor increase in 
maximal dose occurred (due to insufficient dose rebuild-up within the tumour) with 
excellent lung sparing; for medium-sized tumours, increased levels of tumour dose were 
observed (‘hot-spot’ > 140%) with reduced normal lung dose; and for large tumours, 
normal lung dose increased (as larger radiation field sizes limits the extent of LED) with 
minor enhancements in tumour dose.  Thus, we hypothesize that LED-SBRT is best 
suited for treating tumours no larger in diameter than 3 cm, which is applicable to many 
patients with early-staged lung cancer (data for variable tumour sizes may be obtained 
from the authors upon request). 
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3.4.3 Dose calculation algorithms for use with LED-SBRT 
Dose calculation algorithms can be broadly separated into two classes.  The first class of 
algorithms do not consider electron transport, and can greatly overestimate the lung and 
tumour dose distribution by as much as 20% for RT conditions involving LED [49].  
Strictly speaking, class one algorithms should not be used for dose calculation with 
regard to LED-SBRT. 
 Unlike class one, class two algorithms model electron transport in an approximate 
or explicit manner.  Clinically accessible algorithms that approximate electron trajectory 
include: analytical anisotropic algorithm (AAA) [34], collapsed cone convolution (CCC) 
algorithm [50], and recently developed Acuros XB (AXB) algorithm [51].  The AAA and 
CCC algorithm has been deemed acceptable for conditions of moderate electron 
disequilibrium [16, 17, 21, 25] but errors as large as 8% were observed when an 18MV 
small field was used to irradiate a lung phantom [21, 34].    In comparison to the AAA 
and CCC algorithms, the AXB algorithm seems to produce more accurate dose 
calculations within heterogeneous mediums [52, 53, 54, 24, 55].  For example, Han et. 
al., 2011, showed better than 2% agreement when comparing dose distributions produced 
by the AXB algorithm and MC simulation for an 18 MV (2.5x2.5 cm
2
) field incident on a 
heterogeneous phantom [52].  It appears the AXB algorithm may be appropriate for 
calculation of LED-SBRT dose distributions in lung.  However, a future study would be 
useful to validate this assertion, and test the accuracy of the AXB algorithm under 
conditions of extreme LED.  
 Finally, as the Monte Carlo technique explicitly tracks electron range [33], it can 
accurately predict the dosimetric effects of LED in lung tissue.  Recent advances in 
graphical processing units and parallel computing have made MC VMAT simulations 
clinically feasible with computation times on the order of seconds [56, 57, 58, 59].  
Similar MC techniques have already been adopted clinically [e.g. Cyberknife stereotactic 
radiosurgery system (Accuray Inc., Sunnyvale, CA) [60]], and will likely be the 
algorithm of choice for treatment planning of LED-SBRT in the future.  
 
87 
 
3.4.4 Clinical implementation of LED-SBRT 
Our study used 36 equally weighted square or rectangular fields to simulate an SBRT arc 
technique.  This approach was taken in order to understand the basic physical principals 
that govern the dose distribution within the lung and tumour tissues.  In reality, modern 
day SBRT techniques employ volume modulated arc therapy (VMAT) [7, 61] and/or 
intensity-modulated radiation therapy (IMRT) [62], which are capable of optimizing the 
dose distribution with respect to specific constraints. A future study involving a MC 
modelled, LED optimized, VMAT technique [63] may be useful to further improve the 
tumour-to-lung dose ratio using inverse optimization techniques.   
  Beyond dose optimization techniques, the LED phenomenon could be further 
exploited by gating the SBRT delivery.  As the extent of LED is inversely related to lung 
density, further reductions in lung dose could be gained by delivering the radiation during 
an inhale phase of the breathing cycle (i.e. respiratory gating the radiation treatment).  
For instance, Hanley, et al., 1999 [64] and Yorke, et al., 2002 [65] have proposed using a 
deep inspiration breath-hold (DIBH) technique for radiation therapy of lung cancer.  
Hanley et al., suggest that lung density can be reduced from 0.26 g/cm
3
 to 0.19 g/cm
3
 
using DIBH [64].  Also it was reported that DIBH immobilizes the target, improving 
tumour localization, and allows for target margin reduction.  With LED-SBRT, internal 
target volume reduction should be pursued (via 4DCT and gating) in order to reduce the 
tissue heterogeneity of the PTV, and localize high dose levels within the tumour volume.      
 Unfortunately, gated LED-SBRT will involve longer treatment times, which will 
be compounded by attempts to increase tumour dose levels.  A large dose rate is required 
in order to deliver a sufficient amount of monitors units through a small field aperture.  
This may be conceivable using the TrueBeam LINAC in flattening filter free mode where 
dose rates can be up to four times larger (at certain energies; 6MV or 10MV) than 
traditional LINAC technology [66].  Before LED-SBRT can be implemented clinically, a 
future study is required to resolve issues involving: 1) limitations concerning tumour size 
and location within the thorax, 2) toxicity levels in adjacent healthy tissues (including 
peripheral tissues that receive a greater neutron dose at a higher energy), 3) gating and 
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choice of breathing phase, 4) Monte Carlo VMAT optimization, and 5) clinical time 
constraints given the necessity of high dose rates. 
 
3.5 Conclusion 
This article introduces a novel SBRT technique for application to patients with early 
staged lung cancer.  By exploiting the LED phenomenon, we have demonstrated the 
possibility of increasing tumour dose while maintaining or lowering normal lung dose 
levels.  Future work is required to determine the limitations of LED-SBRT 
implementation within a clinical environment, and resolve the controversy concerning 
toxicity of adjacent healthy tissues. 
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Chapter 4  
4 Correction for “artificial” electron disequilibrium due to 
cone-beam CT density errors: Implications for on-line 
adaptive stereotactic body radiation therapy of lung 
This chapter is adapted from the research article, "Correction for “artificial” electron 
disequilibrium due to cone-beam CT density errors: Implications for on-line adaptive 
stereotactic body radiation therapy of lung" published in Physics in Medicine and 
Biology, 2013 Jun 21;58(12):4157-74 by Disher B, Hajdok G, Wang A, Craig J, Gaede S, 
and Battista JJ. 
 
4.1 Introduction 
The clinical workflow for external beam radiation therapy begins by imaging a patient 
using a helical CT scanner to produce a planning CT image (PCT).  The PCT image 
yields quantitative tissue information in the form of CT numbers (i.e. Hounsfield Units or 
HU).  The PCT number data is imported into a treatment planning system (TPS), where it 
is converted to tissue electron density through an HU-to-relative electron density (HU-to-
RED) calibration curve, and then used to calculate a planning CT dose distribution or 
matrix (DMPCT).  The DMPCT represents an ideal prescribed dose distribution, which is 
assumed to be reproducible over all treatment fractions. However, daily deformations of 
patient anatomy and motion of organs, and/or patient set-up variations can lead to 
perturbations of the intended daily dose distribution.  Accumulation of such dose 
variations over multiple fractions can lead to a total delivered dose that does not match 
the prescribed dose distribution (i.e. DMPCT). 
With the advent of image-guided radiation therapy (IGRT), it may be possible to reduce 
the propagation of these dosimetric errors.  IGRT combines an imaging modality with a 
radiation treatment unit. For example, the Varian On-Board Imaging (OBI) system 
integrates the functionality of a kilovoltage CT scanner with a linear accelerator. It can 
generate cone-beam CT (CBCT) images for volumetric reconstruction of the patient’s 
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“anatomy-of-the-day”.  Currently, this technology is used primarily to account for 
geometric errors in patient setup [1]. CBCT information could also be utilized in a 
process referred to as dose adaptive radiation therapy (DART), which accounts for tissue 
deformation through modifications to the delivered dose distribution over the course of 
fractionated radiation therapy [2].   
In general, the DART paradigm can be segmented into five sequential steps (see Fig. 4-
1).  For each treatment fraction (denoted by i), the first step of the process begins by 
acquiring an updated CBCT image of patient anatomy.   Second, the CBCT number data 
is imported into a TPS and converted to tissue electron density through a HU-to-RED 
calibration curve.  The TPS is then used to calculate a CBCT image-based dose matrix 
(i.e. DM
i
CBCT), which can be used to generate a dose-based decision metric (e.g. dose 
volume histogram [DVH], dose difference matrix, tumor control probability, normal 
tissue complication probability, etc.) to prompt for treatment plan re-optimization.  For 
example, the original treatment planning dose, DMPCT, could be subtracted from DM
i
CBCT 
to generate a dose difference matrix, Δi, which represents the dosimetric deviations 
between the PCT and CBCT image sets.  Δi could then be compared to an acceptable 
minimum threshold value (ΔTH).  For Δi > ΔTH, dose differences are severe enough to 
warrant plan re-optimization, which would ideally be carried out on-line using the most 
up-to-date CBCT data set.  Once re-optimized, the i
th
 fraction of radiation is delivered, 
and the entire process is repeated until the prescribed dose to target is achieved. For Δi < 
ΔTH, no re-optimization is required, and treatment delivery proceeds with the next 
fraction of radiation therapy. 
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 Ideally, the dose difference, Δi, should solely be due to geometric variations in 
patient anatomy observed between the original PCT and subsequently acquired CBCT 
images. However, CBCT images are susceptible to artifacts resulting from the cone-beam 
geometry acquisition, including acceptance of scattered photons [3, 4, 5], spectral beam 
hardening and filtration [6], temporal lag in data acquisition [7], and potentially 
respiratory motion [8, 9, 10, 11]. The dosimetric impact of these artifacts has been 
studied extensively using phantoms and/or patient image data for various treatment sites 
including: head & neck, pelvis/prostate, lung, and spine [12, 13, 14, 15, 16, 17, 18, 19, 
20, 21, 22, 23, 24].  The investigations associated with lung patients revealed CT number 
reductions of up to 200 HU [14], and dosimetric errors as high as 5%, when comparing 
PCT and CBCT based plans. Thus, within the context of DART, Δi will be both a 
Figure 4-1 the process of dose adaptive radiation therapy (DART).  Ideally, CBCT images should be used for 
online dose calculation, which prompts a decision regarding treatment plan re-optimization to account for 
variations in patient anatomy or set-up error.  Unfortunately, CBCT image artifacts are observed in images of 
the thorax and can affect decisions regarding DART re-optimization.  RED = HU-to-relative electron density 
conversion curve.  TPS = treatment planning system. DMPCT = prescription dose matrix derived from the PCT 
image set.  DM
i
CBCT = dose matrix produced from the up-to-date CBCT image preceding the next fraction (i) 
of radiation treatment.  Δi = dose difference matrix (DM
i
CBCT - DMPCT). Δthr = a selected dose difference 
threshold upon which dose re-optimization decisions are based. 
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function of patient tissue deformation (i.e.         ) and tissue density errors due to 
CBCT artifacts (i.e.           ): 
                           (4.1) 
Clearly, contributions from Δartifacts must be minimized relative to Δi  because  excessive 
CBCT number inaccuracy may result in 1) ill-founded decisions on the need for plan re-
optimization (Fig. 4-1; Step 4), and 2) erroneous prediction of the accumulated in vivo 
dose distribution (Fig. 4-1; Step 5). 
The absorbed dose in lung strongly depends on its density. In humans, lung density can 
vary up to approximately 0.35 g/cm
3
 [25].  At these densities, the dose distribution is 
affected by two factors: 1) reduced photon attenuation, and 2) enhanced secondary 
electron range.  When electron equilibrium is established, factor 1) dominates, and dose 
is increased to the target within lung and downstream tissues [26].  For conditions of 
lateral electron disequilibrium (LED), factor 2) dominates, and dose within lung and 
tumor tissues can be severely reduced [27]. The impact of any small change in density 
will depend on the state of electron equilibrium. Under equilibrium conditions, several 
investigators reported that a 5% uncertainty in CT-derived tissue density only produced a 
1% deviation in dose calculation [28, 29, 22].  In contrast, under disequilibrium 
conditions, Disher et al., 2012, showed that a 10% reduction in lung HU (-900 HU to -
990 HU) resulted in a 48% reduction in central-axis dose [30].   
Therefore, in order to avoid problems associated with LED, accurate dose calculations in 
lung require high-fidelity CT number data, correct HU-to-RED conversion, and a 
treatment planning system that can account for electron disequilibrium. 
In our investigation, we hypothesize that erroneously low CT numbers from CBCT-based 
images can cause significant dose errors for dose adaptive stereotactic body radiation 
therapy (SBRT) of lung tumors.  Low CBCT numbers within lung tissue will cause 
“artificial” electron disequilibrium, which would in turn artificially reduce the calculated 
dose distribution. In order to demonstrate and quantify the magnitude of artificial LED on 
dose calculations, we use deformable image registration to warp up-to-date CBCT images 
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of a lung cancer test patient onto an original PCT (reference) image.  As a result, dose 
differences between PCT and CBCT image-based plans are no longer related to patient 
tissue deformation (Δpatient = 0), and are solely due to errors in CBCT-derived lung tissue 
density that can potentially produce artificial LED: 
                       (4.2) 
To highlight the extent of CBCT number differences in patient lung tissue, we first 
perform CBCT number analysis using an anthropomorphic thorax phantom.  In addition, 
three practical CBCT number correction methods are developed and tested: 1) lung-
specific HU-to-RED conversion curves to convert raw CBCT numbers to tissue electron 
density using calibration methods,  2) substitution of individual CBCT pixel information 
with bulk CT (BCT) numbers averaged from PCT images for comparable  regions (lung, 
adipose, muscle, and bone), and 3) partial substitution of CBCT pixel information with 
LED-sensitive CT (LCT) numbers that suppress artificial lateral electron disequilibrium 
in lung.  Finally, we discuss the capability of each technique in improving dose 
calculation accuracy for adaptive lung SBRT of three sample patients.  It should be noted 
that dose results are influenced by lung tumour location and size, and differences in lung 
densities between the three patients.  Thus, we report on a particular case that best 
demonstrates the potential dose impacts of electron disequilibrium. 
 
4.2 Materials and Methods 
4.2.1 CT phantoms 
The Gammex RMI TomoTherapy phantom (Gammex RMI
®
, Middleton, WI; referred to 
as the electron density phantom) is a modified version of the Gammex 467 Electron 
Density CT Phantom (Gammex RMI
®
, Middleton WI).  It consists of a 30 cm diameter 
solid water base with a length of 18 cm.  The solid water base contains cylindrical holes 
that can hold multiple tissue-mimicking inserts, each 3 cm in diameter. The inserts vary 
in electron density from 0.28 to 1.69 (lung to cortical bone), relative to water.   
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 The RANDO
®
 phantom (The Phantom Laboratory, Salem, NY) is an 
anthropomorphic phantom that represents human male anatomy.  Three tissue-simulating 
materials are used: 1) a soft tissue material (physical density = 0.997 g/cm
3
), 2) lung 
material (physical density = 0.352 g/cm
3
), and 3) adult skeleton (physical density = 1.3 
g/cm
3
).  The phantom is constructed into the shape of a typical thorax with an 
approximate transverse cross-section (20×30 cm
2
).   
 
4.2.2 CT scanners  
CT images of phantoms and lung patients were obtained using a Philips 16-slice helical 
CT simulator unit (Brilliance Big Bore CT, Philips Inc., Cleveland, OH).  The Philips  
simulator unit was calibrated according to the manufacturer’s specifications (Philips, 
2006), and operated at the following settings: 120 kVp, 400 mAs/slice, 0.5 s rotation 
time, and varying pitch based on the patient’s breathing cycle.  CT images of the lung 
patients were acquired at 10 different phases of the breathing cycle, and a time-averaged 
4D-CT was calculated and designated as the PCT.  Images were reconstructed on a 512 x 
512 pixel matrix over a field-of-view (FOV) of 45 cm for electron density and RANDO 
phantoms, and 50 cm for lung patients.  Slice thickness was fixed to 3 mm.   
CBCT images of phantoms and lung patients were acquired with a Varian OBI unit (V 
1.4; Varian Medical Systems Inc., Palo Alto, CA), which was calibrated according to 
Varian’s user manual (Varian, 2006).  CBCT images of the electron density phantom, 
RANDO phantom, and lung patients were acquired in “thorax mode” with the following 
settings: 110 kVp, 20 mA, 20 ms/pulse, scan length = 16 cm.   For these scans, the 
system was set to half-fan (HF) mode, and used a corresponding bow-tie filter.  In 
general, CBCT image acquisition uses approximately 650 x-ray pulses per rotation, with 
a gantry rotation time of approximately 60 s.  Image reconstruction for the CBCT images 
also spanned a 512 x 512 pixel matrix over a FOV of 45 cm for the electron density and 
RANDO phantoms, and lung patients.  Slice thickness for all CBCT images were set to 
3.0 mm. 
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4.2.3 Deformed CBCT (dCBCT) images 
Inter-fraction organ motion creates variations in patient anatomy when comparing CBCT 
to PCT lung images acquired at different scan times.  These variations contribute to dose 
differences between treatment plans based on either PCT or CBCT image data [13, 18]. 
Image registration software was therefore used to deform CBCT data to PCT images, 
producing a deformed CBCT image set (dCBCT).  The dCBCT image retains CT number 
data from the original CBCT image, but maintains the anatomical geometry from the 
PCT study.  Our registration method, developed in-house, uses the algorithm known as 
ANIMAL (automated non-linear image matching and anatomical labeling) [31, 32].  This 
algorithm uses 3D simplex optimization, and was previously validated in a lung study 
[33] using volumes provided by the Deformable Image Registration (DIR)-laboratory 
group [34].  Following a similar analysis, 3 thorax patients were examined in a separate 
study, and our technique produced a mean registration error of 2.53 mm when comparing 
the dCBCT and PCT image sets [35, 36], even when the fields of view were different.  
Note that in this work, intra-fraction motion effects were not considered as both the PCT 
and CBCT images were acquired with slow scanning protocols to produce time-averaged 
CT numbers.   
 For this level of accuracy, dose differences due to mis-registration between image 
sets should be minimal.  For instance, Yang et al. 2007 purposely introduced registration 
errors of 3 mm between PCT and CBCT image sets of patients.  Their results showed 
negligible dose differences due to registration error (< 1.5%) [13].  In our study, we 
observed greater than 10% differences for dose calculated within the PTV using PCT 
versus deformed CBCT image sets.  The magnitude of these differences is characteristic 
of LED due to ultra-low lung density, not smaller errors in image registration. 
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4.2.4 CT number corrective techniques 
4.2.4.1 CT number (HU) to relative electron density (RED curve) 
Phantoms may be used to produce lung-specific HU-to-RED conversion curve [15, 12, 
20, 21]; however, previous efforts have shown that the chosen phantom should reproduce 
photon scattering conditions for a comparable volume to that of the body region to be 
imaged [20, 21].  We used the large electron density phantom for HU-to-RED conversion 
to create a planning HU-to-RED conversion curve (or REDPCT), and a cone-beam HU-to-
RED conversion curve (or REDCBCT). 
 
4.2.4.2 Bulk CT (BCT) images 
Bulk CT number replacement in large regions of interest may be used to avoid inaccurate 
CBCT number data [37, 38].  In this study, MicroView Analysis
+
 software V2.2 (GE 
Healthcare
®
, Waukesha, WI) was used to create bulk-density images (BCT) of the lung 
patients.   The software has a 3-dimensional (3D) tissue segmentation tool that allowed 
for selection of adipose, lung, muscle, and bone tissue regions from the PCT images of 
the lung patients.  Using these 3D volumetric tissue selections, a single average CT 
number was calculated from the PCT data for each tissue type: PCTadipose= -95 ± 74 HU, 
PCTbone= 404 ± 234 HU, PCTmuscle = 58 ± 25 HU and PCTlung = -746 ± 101 HU. A 
similar process was used to segment the 3D tissues of the dCBCT lung image sets, where 
each dCBCT voxel was replaced with a corresponding regional average tissue PCT 
number.    
 
4.2.4.3 LED-sensitive CT (LCT) images 
 LED enhances the sensitivity of the dose calculation to small variations in lung density, 
and perturbs the dose distribution for SBRT of lung cancer [39].  If lung pixel value 
replacement is to be attempted, the substituted density should offset artificial LED.  
Figure 4-2 displays the relative depth dose factor (RDDF) for a 6 MV (3x3 cm
2
) photon 
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field that represents the equivalent fields used in our volume modulated arc therapy 
(VMAT) plan for our case study (i.e. one of the three patients).  The critical lung density 
that causes severe LED (RDDF ~≤ 0.8) is approximately 0.2 g/cm3 or -800 HU, and is 
used as the CT number threshold for selective pixel substitution.  This value is predicated 
on avoiding the region of Fig. 4-2 where the RDDF is strongly dependent on density.  
Fig. 4-3 shows histograms of CT number data acquired from the lung tissue within PCT 
and dCBCT data sets for this patient. Within the PCT image, we selected pixels with 
values below the threshold (-800 HU) and calculated an average LCT number, LCT = -
882 +/- 39 HU.  Next, all pixel values below the threshold within the dCBCT lung 
volume were selected, and only these pixel values were replaced with the average LCT 
number.  In this way, we produced density maps that are more representative of true 
density, and do not induce artificial LED.  This process was repeated for the remaining 
two lung patients. 
RDDF maps were produced from the PCT, dCBCT, BCT, and LCT image sets to map 
regions of expected electron disequilibrium and to explain observed dosimetric 
differences.  These disequilibrium maps were estimated by converting CT number data to 
tissue density using a HU-to-density curve derived from PCT images of the electron 
density phantom. Then, each pixel-by-pixel density value was converted to a 
corresponding RDDF number using the relation below: 
                  (   (                (4.3) 
where ρ represents the CT-derived tissue density per pixel.  SigmaPlot V.11 (Systat 
Software Inc., Chicago, IL) was used to determine equation (4.3) by fitting an 
exponential function to the data displayed in Fig. 4-2. 
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Figure 4-9 shows the Relative Depth Dose Factor (RDDF) [30] for a 6 MV (3x3 cm
2
) photon 
field – the radiation therapy parameters that approximately match the clinical situation described 
herein.  Note that the RDDF << 1 for lung densities below 0.2 g/cm
3
, which indicates the onset of 
severe LED.  This threshold was chosen in order to avoid the region where the RDDF was 
strongly dependent on density (i.e. the region indicated to left and below the dotted line shown 
above). 
Figure 4-3 displays CT number histograms acquired from the lung tissue within PCT and dCBCT 
image sets. The dCBCT lung histogram is largely populated by ultra-low artificial lung densities 
(< 0.1 g/cm
3 
or -900 HU). 
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4.2.5 Dose calculations with treatment planning system (TPS) 
For radiotherapy planning purposes, the PCT, dCBCT, LCT and BCT image sets for all 
three lung patients were entered into the Philips Pinnacle
3
 TPS (Philips Medical Systems, 
Madison, WI) for inverse plan optimization. Note that we only report the treatment 
parameters relevant to the example case study; however, a similar approach was used to 
treat all three patients.  A planning target volume (PTV) contour was created to cover the 
full range of tumour motion over the breathing cycle (volume ≈ 10 cm3).  6 MV beams 
(field size ≈ 3x3 cm2) were centered on the tumor using a 225o VMAT technique, as is 
commonly used in our center.  The approximate 3x3 cm
2
 field size was determined by 
calculating the equivalent square field size per VMAT segment in accordance with the 
following equation: 
   
∑ (    (      
 
 
∑ (    
 
 
          (4.4) 
where FS is the fluence-weighted average field size, N is the total of segments (i.e. beam 
angles), i is the individual segment, MUi is the monitor unit per segment, and ESFSi is the 
equivalent square field size per segment.  FS was used to determine an appropriate RDDF 
equation, which is beam energy and field size dependent. 
The VMAT plan was designed such that the constraints of the ROSEL study [39] were 
satisfied using the PCT data set for dose calculation.  The planned dose prescription was 
set to 54 Gy (delivered in 3 fractions) to 95% of the PTV (i.e. D95 prescription).  The 
monitor units (MUs), beam geometry, and contours from the PCT plan were copied “as 
is” onto dCBCT, LCT, and BCT image-based treatment plans. A 3D dose grid spacing of 
0.25×0.25×0.25 cm
3
 was used for dose calculations. As well, dose results were analyzed 
using Computational Environment for Radiotherapy Research [40] software run within 
Matlab R2012a (The MathWorks Inc., Natick, MA). For consistency of 
intercomparisons, the collapsed cone convolution (CCC) algorithm was selected for dose 
computations as it is a commercially available clinical option.  The suitability of the CCC 
algorithm for accurate dose calculation under SBRT conditions has been assessed by 
multiple authors [27, 41, 42, 43, 44, 45].  These investigators report dose calculation 
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inaccuracies between 1-4% using the CCC algorithm.  In our study, observed dose 
differences between the various image-based plans were greater than the 1-4% range, 
which is indicative of dose variations due to changes in CT-derived density under 
conditions of LED. Finally, we refer the reader to Table 4-1 for a review of the 
experimental design. 
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Table 4-1 A summary of techniques referred to in this work.  The PCT is a time averaged 
multi-slice helical CT image of the patient (our standard for comparison). The CBCT data 
set is the originally acquired cone-beam CT image of the patient.  Whereas the dCBCT 
image contains CBCT image data, but deformed onto PCT geometry.  The BCT image 
set is derived from the deformed cone-beam CT image of the patient using pixel-by-pixel 
replacement with bulk substitutes created from different tissues within the PCT (lung, 
adipose, muscle, bone).  The LCT image set is a modified version of the dCBCT, where 
only specific lung pixels are replaced with a LED sensitive substitute originating from the 
PCT. The REDPCT was derived from multi-slice helical images of the electron density 
phantom.  The REDCBCT was derived from CBCT images of the electron density 
phantom.  The treatment planning system used the REDPCT curve to convert PCT, 
dCBCT, LCT, and BCT image sets to tissue electron density.  As well, the feasibility of 
converting dCBCT numbers to an accurate tissue electron density was tested by using the 
REDCBCT curve.  Five dose distributions were calculated for the same VMAT plan: PCT 
Dose (as the fixed reference for all comparisons), LCT Dose, BCT Dose, dCBCT Dose 
(REDPCT), and dCBCT Dose (REDCBCT). 
 
CT 
Data 
Image 
Source 
Deformation 
Required? 
Pixel 
Substitution 
Source of CT 
number data 
HU-to-RED 
Conversion 
PCT  PCT No N/A PCT REDPCT 
dCBCT CBCT Yes N/A CBCT REDPCT  
dCBCT CBCT Yes N/A CBCT REDCBCT  
BCT CBCT Yes Regional 
tissue-based 
Average tissue 
PCT numbers 
REDPCT 
LCT CBCT Yes LED 
threshold-
based 
CBCT and 
average PCT 
lung numbers 
REDPCT 
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4.3 Results 
4.3.1 RANDO phantom and lung patient CT image data 
We obtained PCT and CBCT images of the RANDO phantom, displayed in Figs. 4-4 (a) 
and (b).  Note the CBCT shadow artifacts in the region of the spine and periphery of lung 
in Fig. 4-4 (b).  Figures 4-5 (a) and (b) display a PCT and dCBCT image for the lung 
patient case study, respectively.  The image quality of the dCBCT lung was inferior 
compared to the PCT image.  Many image regions showed shadow, blur, and streak 
artifacts, and it was challenging to distinguish muscle from fat.  Quantitatively, Figs. 4-5 
(c) and (d) compare the PCT and dCBCT lung densities below 0.2 g/cm
3
 or -800 HU. 
The dCBCT image contained many artificially low density regions.  
    (a)  RANDO PCT     (b)  RANDO CBCT 
 
 
 
 
Figure 4-4 (a) PCT image and (b) CBCT image of the RANDO phantom.  The red line 
indicates where CT number comparisons are made in Figure 4-6. Notice the CBCT 
shadow artifacts in Fig. 4-4 (b).  
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    (a)  Lung patient PCT    (b) Lung Patient dCBCT 
 
 
 
 
 
   (c)  Lung patient PCT number map             (d) Lung Patient dCBCT number map 
 
 
 
 
 Figure 4-6 displays the CT number profiles acquired from the PCT and CBCT 
images of the RANDO phantom.  In general, the CBCT profile shows values less than the 
PCT profile (reduction of 200 HU).  Figure 4-7 displays the CT number profiles acquired 
for the planning CT, deformed cone-beam CT, LED-sensitive CT and bulk CT image sets 
of the lung patient.  The BCT number profile is set to a fixed average value of -746 HU 
for the entire dCBCT lung volume.  The LCT number of -882 HU was used to substitute 
Figure 4-5 (a) Planning CT (PCT) image and (b) deformed CBCT (dCBCT) image of the 
lung patient.  The red line indicates the image profile region where CT number comparisons 
were made in subsequent figures.  Please note that the profile is within the lung tissue 
proximal to the tumor.  Figs 4-5 (c) and (d) display CT number intensity colour maps of lung 
tissue within the PCT and dCBCT patient images (level = -900 HU, window = +/- 100 HU).  
Figure 4-5 (d) shows that dCBCT lung tissue appears much lower in density. 
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only those dCBCT lung pixels that produce LED (dCBCT number ≤ -800 HU). Note that 
the majority of the dCBCT numbers were less than the corresponding PCT numbers in 
lung.  In particular, dCBCT numbers were as low as -1000 HU (0 g/cm
3
), a density 
corresponding to vacuum. This outcome is non-physical, and resulted from CBCT 
artifacts.  More importantly, the severity of CBCT number undervaluation is worse in the 
lung patient than in the RANDO phantom [compare Figs. 4-4 (b) and 4-5 (b)], implying 
that a static thorax phantom does not adequately model respiratory motion. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6 CT number profiles extracted from the PCT and CBCT images of the 
RANDO phantom (see Figs. 4-4 (a) and (b) for profile location).  CBCT numbers are 
reduced by as much as 200 HU, compared with PCT data. 
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4.3.2 Dose comparison using CBCT corrective techniques  
Figure 4-8 compares the VMAT calculated dose distributions using the planning CT, 
deformed cone-beam CT, bulk CT, or LED-sensitive CT lung images.  Figure 4-8(a) 
shows the PCT image of the example lung patient with the calculated dose distribution 
overlaid on anatomy (to serve as the control case for inter-comparison).  Figures 4-8(b) - 
(e) display the PCT image of the lung patient with overlying dose distributions calculated 
from the dCBCT, BCT, and LCT image sets. Figures 4-8(f) - (i) all present the PCT lung 
image with dose differences, Δ (Δ = x – PCT dose, where x is the dose based on test cases 
of either dCBCT images with REDPCT or REDCBCT conversion, bulk CT, or substituted 
LED-sensitive CT numbers).   
Figure 4-7 CT number profiles extracted from the PCT, LCT, dCBCT, and BCT 
images of the lung patient (see Figs. 4-5 (a) and (b) for profile location).  An average 
lung BCT number of -746 HU was calculated by averaging all of the CT numbers 
from the entire PCT lung volume.  A lung LCT number was calculated by averaging 
only those CT numbers that establish LED from the PCT lung volume.  The dCBCT 
numbers undervalue the PCT numbers. 
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 The dose distributions in Figs. 4-8(a) – (e) have similar value and shape in the 
low dose and shallow dose-gradient regions.  In regions where there is high dose and 
steep dose-gradients (in the vicinity of the PTV) there are large dose discrepancies.  The 
dose difference distribution in Fig. 4-8(f) shows that the dCBCT image-based plan, based 
on REDPCT conversion, exhibits lower dose regions with Δ ≤ - 5.4 Gy (i.e. ≤ 10% of the 
prescription dose).  Comparatively, Fig. 4-8(g) shows that the dCBCT image-based plan 
using REDCBCT conversion under-values the dose near the PTV to a lesser extent, and the 
depressed dose region encompasses a smaller region.  On the contrary, Fig. 4-8(h) shows 
that the BCT lung plan yielded a dose increase (Δ ≥ 5.4 Gy) in lung tissue.  Figure 4-8(i) 
shows that the LCT image-based plan produced a dose distribution that closely matched 
the PCT based plan, with minimal Δ in the vicinity of the tumor. 
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      1 
       (a) PCT dose            (b) dCBCT dose (REDPCT)  (c) dCBCT dose (REDCBCT )        2 
 3 
 4 
      (d) BCT dose             (e) LCT dose           (f) Δ = dCBCT (REDPCT ) – PCT                       5 
 6 
 7 
           (g) Δ = dCBCT (REDCBCT) – PCT        (h) Δ = BCT – PCT                               (i) Δ = LCT – PCT                       8 
 9 
 10 
Figure 4-8 (a) - (e) shows the PCT, dCBCT, BCT, or LCT VMAT dose distributions overlaid on the PCT image. Figs. 
4-8 (f)-(i) show the dose differences, Δ, overlaid on the PCT image.   The largest differences occur in regions with steep 
dose gradients. 
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 Figure 4-9 compares the dose-volume histograms (DVHs) for the PTV (note the 
magnified view). The D95 for the PCT, LCT, BCT, dCBCT(REDPCT), and 
dCBCT(REDCBCT) image-based plans were 54Gy, 56Gy, 59Gy, 47Gy, 52Gy.  Both PTV 
structures from the dCBCT (REDPCT) and dCBCT (REDCBCT) plans produced DVHs that 
received less dose to a smaller volume (poorer coverage) when compared to the PCT 
planning target volume. These results are clinically unacceptable as the D95 prescription 
criterion (i.e. 54Gy) was not met.  In contrast, the PTV from the BCT image-based plan 
produced a DVH that generally received more dose, while the DVH from the LCT plan 
matched the PCT DVH the closest. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9 shows dose volume histograms comparing calculated VMAT dose for the 
planning target volume (PTV) using either the PCT, LCT, dCBCT (REDPCT), dCBCT 
(REDCBCT), or BCT image-based plans. The LCT DVH most closely matched the PCT 
DVH. 
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4.4 Discussion  
4.4.1 Disequilibrium maps  
Figure 4-10 displays the Relative Depth Dose Factor maps corresponding to the PCT, 
dCBCT, BCT, and LCT image sets (location of the each map was selected to match that 
shown in Fig. 4-5) for the test patient.  These results can be interpreted as lateral electron 
disequilibrium maps, and provide a physical basis for understanding the dosimetric 
results (see Fig. 4-8).  Under these treatment conditions, lateral electron disequilibrium is 
established for lung densities of 0.2 g/cm
3
 or lower (< -800HU) [see Fig. 4-2] for a 
comparable field size.  Figure 4-10 shows lung regions that create LED (RDDF < 1), and 
cause reductions in central-axis depth dose. 
 (a) RDDF PCT     (b) RDDF dCBCT 
 
 
 
 (c) RDDF BCT     (d) RDDF LCT 
 
 
 
 
 
 
 
 
Figure 4-10 shows the Relative Depth Dose Factor (RDDF) maps acquired from the 
PCT, dCBCT, BCT, and LCT image sets. These maps (calculated using data from Fig. 
4-2) provide regional information concerning the estimated magnitude of LED.  The 
RDDF value quantifies the extent/severity of LED, and regions of lung tissue that are 
more apt to establish LED are easily identified. 
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 For example, the planning CT image contains many contiguous lung densities that 
produce LED [see Figs. 4-5 (c) and 4-10 (a)], and we expect a true decrease in dose in 
these regions.  The deformed cone-beam CT lung image contains many erroneous ultra-
low pixel values (< -900 HU) [see Fig. 4-5 (d)], which produced an under-valued RDDF 
map causing severe artificial LED [see Fig. 4-10 (b)]. As a result, the dose is drastically 
reduced in these regions due to the effects of exaggerated LED.  Conversely, using the 
BCT lung image for dose calculation over-estimated the dose in lung tissue.  By setting 
the entire lung to an average PCT number equal to -746 HU or 0.254 g/cm
3 
(a lung 
density > 0.2 g/cm
3
), electron equilibrium is artificially maintained [RDDF ~ 1; see Fig 
4-10 (c)], and dose in lung tissue is enhanced due to preserved photon fluence, as 
predicted by simpler dose calculation algorithms [46].  Substituting only those dCBCT 
lung pixels that cause artificial LED with an appropriate CT number (-882 HU), produced 
an LCT RDDF [see Fig 4-10 (d)], which is similar, but not identical to the RDDF PCT 
map.  Thus, the VMAT LCT image-based dose distribution was more representative of 
the reference PCT dose.  Note these results are only relevant for a 6 MV (3x3 cm
2
) 
photon source.  The RDDF varies for different combinations of beam energy, field size, 
and lung density.  A unique RDDF should be produced to match the clinical treatment 
conditions [30]. 
 It should be noted that the results described above are specific to the example test 
patient.  The dose distribution within the tumour and lung tissues are affected by tumour 
location, size, and patient lung density.  For example, a similar analysis was performed 
on two additional patients with tumours located within lung tissue at the chest wall 
interface.  Dosimetric comparison of the correction techniques (i.e. D95 analysis) 
revealed similar trends as described above, but with dose differences of a smaller 
magnitude.  For RT conditions involving electronic equilibrium (e.g. large lung tumours 
adjacent to soft tissues) differences between corrective techniques maybe marginal. 
However, for circumstances that enhance LED (e.g. small tumours entirely embedded 
within lung tissue), substantial dose variations with the corrective methods maybe 
observed. 
 
120 
 
4.4.2 Recommendations 
4.4.2.1 Dose calculations with uncorrected CBCT thorax images 
The direct use of CBCT lung patient data in a TPS is not recommended. This will 
produce artificially low dose results in lung tissue and tumour and lead to incorrect 
decisions in DART.  Clinically, an unsafe over-dosage would be prescribed to the patient 
to counter the artificial under-dosage.  For example, considering results from all three 
patients, an increase in the prescription dose of 2 to 7Gy (or 4 to 13%) was required to 
counter the artificially low dose results produced by the dCBCT (REDPCT) image-based 
VMAT plan. 
 
4.4.2.2 Thorax specific HU-to-RED conversion curve 
The use of a static phantom for conversion of lung CBCT numbers to tissue electron 
density is also not recommended.  We scanned both the electron density and RANDO 
phantoms using the same CBCT parameters (OBI V1.4) used to scan thorax patients.  
The CBCT artifacts in images of the phantoms were not as severe as those artifacts seen 
within CBCT images of lung patients.  The CBCT numbers of plastic lung tissue within 
the RANDO or electron density phantom were not as low as -1000 HU; and hence an 
accurate HU-to-RED conversion curve (i.e. REDCBCT) could not be derived using the 
static electron density phantom.  Consequently, the dCBCT image-based plan using the 
REDCBCT produced an artificially low calculated dose to lung tissue and tumour for the 
case study.  Considering results for all three patients, the D95 ranged from 51.5 Gy up to 
57.5 Gy, which represents dose variations with respect to the prescription dose of -5% 
and 6%, respectively.  
Guan & Dong, 2009 and Hatton et al., 2009 have shown that the CBCT HU-to-RED 
conversion curve is highly dependent on the phantom’s plastic composition, pin size, 
radial and longitudinal dimensions, and x-ray scatter volume [21, 20].  These studies did 
not account for the additional effects of lung patient breathing motion.  We expect that 
additional CBCT lung image artifacts found in patient data (not seen in static phantoms) 
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are due to patient respiratory motion [8, 9, 11, 47, 13].  A more accurate HU-to-RED 
curve may be derived from a deformable “breathing” lung phantom containing tissue 
equivalent plastics. For example, Serban et al., 2008 and Court et al., 2010 have 
developed such a phantom, and a future study focused on CBCT HU-to-RED stability 
under breathing conditions may be useful [48, 49]. 
 
4.4.2.3 Bulk CT Substitution 
Replacement of the entire CBCT lung volume with one average CT number is not 
recommended.  Pixel replacement of patient lung CBCT numbers with a fixed average 
PCT number may enforce electron equilibrium in regions were true LED has occurred, 
and this will result in artificially high dose values.  In order to compensate clinically, as 
observed in all three patients, an under-dosage ranging from 0.5 Gy up to 5 Gy (1%  to 
9%) would be prescribed to the patient.   
 
4.4.2.4 LED-sensitive CT number substitution 
Partial volume substitution of the CBCT lung volume is recommended.  We observed 
marked improvements in dose distributions when a threshold setting was used to 
selectively replace dCBCT lung CT numbers that cause artificial lateral electron 
disequilibrium.  Therefore, given a specific plan and knowledge of treatment parameters 
that establish LED, and a trustworthy dose algorithm, one can use the local RDDF 
parameter to guide the selective replacement of CBCT lung density.  In terms of dose 
calculation accuracy, the results shown here-in suggest that the LCT image-based dose 
distribution is comparable to the PCT-based reference for SBRT of three lung cancer 
patients.  However, a future study involving a greater number of patients, tumour sizes 
and locations is required to fully assess the accuracy and limitations of the LCT 
substitution technique. 
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 Currently, efficient DART may be possible using the LCT substitution technique 
as this method could save considerable time while the patient is on the treatment table.  A 
five step process is required to carry out the LCT method: 
1.  Determine the RDDF(ρlung) function for the desired RT parameters (see Fig. 4-2) using 
a lookup table or database [30]. 
2. From the RDDF(ρlung) curve, decide on the threshold lung density, ρthr, that establishes 
lateral electron disequilibrium (RDDF(ρlung) < 1). 
3. Apply ρthr to the originally acquired PCT lung data (selecting only pixels with PCTlung 
< ρthr) and calculate an average CT number (i.e. LCT) for this subset of low-density 
pixels. 
4. Upon acquisition of the up-to-date CBCT image, replace only those CBCT lung pixels 
with densities less than the threshold (CBCTlung < ρthr ) with the average LCT number, 
forming the new LCT image set, avoiding artificially low densities caused by CBCT 
artifacts. 
5. Calculate “dose distribution of the day” using the LCT image set. 
Steps 1-3 could be conducted off-line before delivery of the first fraction of radiation.  
Step 4 could be performed on-line and easily automated so that completion time was 
seconds or less.  Step 5 is also performed online, and limited by the calculation speed of 
the TPS. 
 
4.5 Conclusion  
Our study demonstrates that CBCT artifacts can cause severe undervaluation of CBCT 
numbers in patient lung tissue, and erroneous perception of electron disequilibrium.  This 
has the potential for misleading increases in delivered dose for adaptive radiotherapy in 
SBRT.  Furthermore, such density-driven dose errors generally impair the decisions on 
dose re-optimization based on inaccurate cumulative dose distributions.  We therefore 
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cannot recommend using CBCT lung images “as is” for solitary lung tumours treated by 
small-field radiation therapy.  CBCT number correction techniques must be invoked for 
the thorax until suitable strategies are developed to overcome artifacts due to photon 
scattering and respiratory motion.  Selective LED-sensitive substitution of pixel values 
considerably improves dose computation accuracy.  
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Chapter 5  
5 Conclusion and Future Work 
 
5.1 Summary and Conclusions 
The following sections summarize each chapter, and present the overall conclusions from 
the thesis. 
5.1.1 Radiation parameters that cause lateral electron 
disequilibrium (LED)  
In chapter 2 of the thesis, we used Monte Carlo (MC) simulations to characterize the 
radiation therapy (RT) parameters that can cause LED.  The analysis considered various 
combinations of beam energies (Co-60 up to 18 MV x-rays), field sizes (1×1 cm
2
 up to 
15×15 cm
2
), and lung densities (0.001 g cm
−3
 up to 1 g cm
−3
) in a phantom geometry.  
We also examined the dosimetric effects of LED on the dose distribution within, and in 
the vicinity of, a simulated small lung tumour.  In general, the dose within lung tissue 
was enhanced for decreasing lung density, as expected under conditions of charged 
particle equilibrium (CPE).  However, at a specific ‘critical lung density’, this trend was 
broken, and a drastic reduction in lung dose was observed indicating the onset of LED.  
To determine the transition from CPE to LED conditions, we developed the relative depth 
dose factor (RDDF), which varied according to the extent of CPE disruption from 
equilibrium (RDDF ~ ≥ 1) to disequilibrium (RDDF < 1) status. This metric is useful for 
approximating the severity of LED, and central-axis depth-dose reduction.  With regard 
to tumour dose levels, large reductions were present at the tumour periphery under 
conditions of LED.  At the tumour core, the level of dose depends on the tumour size, 
which can “re-build up” CPE to an extent.  As smaller tumours lack the necessary depth 
to achieve full dose build-up, higher energy beams (e.g. 18 MV) may under-dose the 
tumour core for conditions involving LED. 
 In order to avoid these negative dosimetric effectives, clinicians can use the 
RDDF metric to guide the selection of appropriate RT parameters, and/or suitable dose 
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calculation algorithms (superposition/convolution or MC techniques) for clinical trials 
involving small field treatment of lung cancer (e.g. SBRT).  Further, at ultra-low lung 
densities (ρlung < 0.1 g/cm
3
), LED was shown to be unavoidable.   This greatly impacts 
the radiation treatment planning of emphysematous lung cancer patients where large 
pockets of air (ρ ~ 0.001 g/cm3) remain trapped in the lung. In such cases, that are not 
uncommon for lung patients – careful consideration of LED is required in these 
circumstances [1].  Finally, under conditions of LED, it was discovered that the lung dose 
distribution became hyper-sensitive to small variations in density.  This is of importance 
for adaptive SBRT planning where CT density is derived from cone-beam CT (CBCT) 
that is not as quantitative (yet) as diagnostic fan-beam CT.  CBCT systems are more 
susceptible to artefacts and miscalibrations [2], and CBCT-derived density may be less 
accurate in lung tissue producing erroneous levels of LED and incorrect dose results.  
This issue was further explored in chapter 4 of the thesis. 
 
5.1.2 Development of a novel SBRT technique to exploit LED 
In chapter 3 of the thesis, we proposed a novel form of SBRT, called LED-optimized 
SBRT (LED-SBRT), which used specific radiotherapeutic (RT) parameters (derived from 
Chapter 2) to disrupt CPE purposely, with the aim of sparing healthy lung.  In this work, 
MC simulations of a phantom and lung cancer patient were used to demonstrate the 
dosimetric effects of LED-SBRT.  Further, we introduced a new ‘clinical tool’, i.e. LED 
maps, which can be used to visualize the magnitude and spatial distribution of LED for 
SBRT of a lung patient.  To demonstrate the potential lung sparing capability of LED, we 
simulated SBRT arcs using 6 MV or 18 MV x-ray beam energies, collimated to various 
field sizes.  Results from phantom simulations suggest that LED-SBRT can produce 
extremely steep dose gradients at the lung/tumour boundary, increased levels of tumour 
dose, while maintaining or reducing the normal lung dose.  For example, comparing the 
normal lung dose at distance 2 cm away from the tumour edge, reductions of ~ 70% were 
observed using the LED-optimized arc (18 MV [1x1 cm
2
]) as opposed to the 18 MV [5x5 
cm
2
] arc. In addition, the 18 MV [1x1 cm
2
] arc resulted in a central tumour hot spot 
>125%, while still providing adequate dose coverage at the tumour edge (100%).  
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Similarly in the patient simulation, the LED-optimized plan [18 MV (3x1 cm
2
)] increased 
the maximal, mean, and minimal tumour dose by as much as 80Gy, 11Gy, and 3Gy when 
compared to a more conventional SBRT arc [6 MV (3x3 cm
2
)].  Also, the 18 MV (3x1 
cm
2
) arc reduced or maintained lung dose metrics (i.e. MLD, V20, V5) at an acceptable 
level for the patient simulation. 
 We conclude that LED-SBRT has the potential to increase tumour dose levels, 
while at least maintaining the well-tolerated lung dose profile currently observed using 
traditional SBRT techniques.  The hypothetical benefits of tumour dose elevation include: 
higher tumour control, improved radiobiological effects (tumour hypoxia), and hence 
better overall survival rates [3, 4, 5, 6, 7].  Further, lower values of lung dose metrics may 
reduce related lung toxicities such as pneumonitis and fibrosis [8, 9, 10].  With LED-
SBRT, the balance between tumour dose elevation, tumour dose inhomogeneity, and lung 
sparing directly depends on the choice of beam parameters and patient conditions.  
Through manipulation of these parameters, physicists and dosimetrists can improve the 
tumour/lung dose distribution as desired.  However, LED-SBRT treatment planning must 
also be in accordance with current SBRT protocols to ensure patient safety [11].  Future 
work will resolve remaining issues concerning tumour size and location, treatment 
delivery, and the controversial subject of tumour dose escalation versus dose 
homogeneity (see Section 1.2.3 below). 
 
5.1.3 Cone-beam CT image-based lung dose calculations 
In chapter 4 of the thesis, we assessed the suitability of using CBCT thorax images 
directly for adaptive dose computations.  Currently, CBCT images of thorax patients are 
only being used for patient set-up.  Ideally these images could also be used for ‘on the 
fly’ adaptive dose calculations to account for daily deformations in patient anatomy 
during the course of radiotherapy.  Unfortunately, CBCT images of the thorax are subject 
to cupping and respiratory artefacts due to an increased CBCT scanning volume 
(producing an elevated scatter-to-primary x-ray ratio), and slow scan times (~ 1 min).  
The resultant CBCT number data (HU) are generally inaccurate, and will negatively 
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impact the accuracy of calculated SBRT tumour and lung dose distributions.  Thus, the 
goal of this work was to determine the extent of CBCT number error in lung tissue, and 
its resultant effect on CBCT-derived lung density and computed dose accuracy.  To this 
end, we compared planning CT (PCT) based dose calculations to CBCT-based results for 
three typical early-staged lung cancer patients.  Comparison of CT number data within 
lung showed CBCT-derived lung density was severely undervalued, down to -1000 HU 
(or vacuum).  Using the RDDF as a guide-line (from Chapter 2), we determined that 
erroneously low CBCT-derived lung density artificially disrupts CPE.  As a result, CBCT 
image-based dose calculations underestimated the tumour prescription dose by as much 
as 13% compared to PCT based results. 
  In an attempt to correct inaccurate CBCT-based dose results, we proposed three 
CT number corrective techniques: 1) conversion of CBCT numbers to accurate tissue 
electron density using a ‘thorax sized’ calibration phantom, 2) ad-hoc replacement of 
CBCT pixels with four ‘bulk’ CT numbers (representing muscle, adipose, bone, and 
lung) derived from PCT images, and 3) selective replacement of CBCT lung pixels that 
were the most likely to cause artificial LED in dose calculations.  Unfortunately, an 
accurate HU-to-relative electron density (HU-to-RED) conversion curve could not be 
obtained from CBCT scans of the phantom; CBCT number error in patient data was 
worse than in static phantom images.  It was hypothesized that CBCT artefacts due to 
respiratory motion were poorly accounted for by scanning a static phantom, and resultant 
dose calculations could not reproduce the PCT based results.  Bulk replacement of the 
heterogeneous lung tissue with a global average CT number also produced inaccurate 
dose results.  By setting the entire CBCT lung to one average PCT number, real LED was 
not accounted for correctly in dose calculations, and resultant tumour dose was 
erroneously high up to 9% (relative to the prescription dose of 54 Gy).  Selective 
replacement of CBCT lung pixels improved dose calculation accuracy considerably and 
represented a practical approach to localized density correction.  However, it was 
concluded that a future study is required in order to the further assess the accuracy and 
limitations of this technique in clinical practice (see Section 1.2.4). 
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5.1.4 Conclusions 
The overall goal of this thesis was to determine the impact of lateral electron 
disequilibrium (LED) on stereotactic body radiation therapy of lung cancer.  This goal 
motivated the following research questions: 
Q1 What combination of radiation field size, energy, and lung density, cause the LED 
 phenomenon to occur? 
Q2 How sensitive is the dose distribution in LED regions to CT-derived lung density? 
Q3 How do we design a new SBRT technique that forces LED to occur in order to  
 produce “spikes” of highly localized dose in small tumours, relative to 
 surrounding lung?   
Q4 How does CBCT-derived lung density affect the lung and tumour dose 
 distribution? 
Q5 Are lung CBCT numbers correctable for the purpose of accurate dose 
 calculation? 
Q1 and Q2 were addressed within chapter 2 of the thesis.  The incidence of the LED 
phenomenon is dependent on a combination of three “perfect storm” factors: beam 
energy, field size, and density.  The phenomenon is most likely to occur when beam 
energy is high (> 10 MV), field size is small (< 5x5 cm
2
), and density low (< 0.4 g/cm
3
).  
The combination of parameters that cause LED was quantified through the development 
of the relative depth dose factor [RDDF] (Q1).  It was noted that the lung dose 
distribution experienced heightened sensitivity to lung density once LED was precipitated 
by regionally low density (Q2).  Therefore, inaccurate CT-derived lung density, seen in 
CBCT scanning, can greatly affect dose calculation accuracy under these conditions.  Q3 
was addressed within chapter 3 of the thesis.  By choosing SBRT parameters that 
enhance LED, it was possible to create steep dose gradients at the lung/tumour interface.  
These parameters can be determined a priori using the RDDF and the radiation physics 
knowledge gained from Chapter 2.  Q4 and Q5 were considered in chapter 4 of the thesis.  
136 
 
The combination of CBCT image artefacts (e.g. cupping, streaking and blurring) 
erroneously reduced CBCT-derived lung density, artificially creating LED, which 
inaccurately reduced the calculated tumour and lung dose distribution (Q4).  Replacing 
artificially low CBCT lung pixels with a value that is more representative of true lung 
density (derived from the corresponding PCT image), improved dose calculation 
accuracy (Q5).   
 With regard to SBRT of lung cancer, the results of this thesis will provide 
physicians and physicists with: 1) knowledge concerning the RT parameters that can 
cause LED, 2) confidence in choice of LED-competent dose calculation algorithm, 3) 
means to avoid the potential negative dosimetric effects of LED, and 4) new techniques 
to gain dosimetric advantages for early-staged lung cancer patients.   These contributions 
will help in the design of SBRT clinical trials so that lung cancer patients may experience 
improved SBRT treatment related outcomes (e.g. tumour control and overall survival 
with fewer severe complication rates).    
 
5.2 Future Work 
5.2.1 Generalize the relative depth dose factor (RDDF) to other 
forms of modern radiation therapy 
In chapter two of the thesis, the RDDF was developed using single fields of radiation, 
and homogeneous phantoms.  This approach was taken in order to simplify the 
interpretation of the radiation physics of CPE and LED for the SBRT technique.  
Advanced radiotherapy techniques, such as intensity-modulated radiation therapy 
(IMRT) and volume modulated arc therapy (VMAT), use multiple fields of radiation 
where heterogeneous photon fluence patterns are optimized according to treatment 
planning constraints.  Further, patient lung tissue consists of heterogeneous density.  The 
ability of the RDDF (or a similar metric) to predict the prevalence of LED under these 
instances needs to be assessed using a reliable Monte Carlo modeled VMAT/IMRT dose 
distribution [12].  Such an “LED alarm” tool would alert treatment planners to either 
avoid or exploit LED during IMRT or VMAT. 
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5.2.2 SBRT for lung cancer patients with emphysema 
Within chapter 2 of the thesis, it was noted that LED was unavoidable (across all beam 
energies, and field sizes) for lung densities below 0.1 g/cm
3
.  This result is relevant for 
conditions involving SBRT treatment of lung cancer patients who are also afflicted by 
emphysema.  Emphysematous lung tissue contains air pockets with densities as low as 
0.001 g/cm
3
 [13].  When tumours are located adjacent to these regions, required SBRT 
protocols are much more challenging to fulfill [1].  A future study focused on the effects 
of emphysematous lung on SBRT dose distributions would be useful.  These patients may 
preferentially benefit from LED-optimized SBRT (discussed in Chapter 3), where LED 
could be used to increase tumour dose levels. 
 
5.2.3 LED-optimized SBRT: clinical implementation 
In Chapter 3 of the thesis, we proposed a novel SBRT technique designed to cause LED 
for advantage.  In our approach, we used a simplified arc technique involving 36 equally 
weighted fields, collimated into rectangular or square field sizes.  This was done in order 
to facilitate interpretation of the underlying physics.  In reality, more complicated 
radiation treatment methods such as VMAT are more clinically relevant.  The next step in 
the progression of LED-SBRT should involve a Monte Carlo modeled, LED-optimized, 
VMAT technique (i.e. LED-VMAT) [12].  With LED-VMAT, we will assess the efficacy 
of this method in a real patient population exposed to today’s popular forms of arc 
therapy. 
 Future work should be organized into a three phase study.  The first phase would 
be a retrospective study, where dose distributions derived from standard SBRT 
techniques could be compared against results using LED-VMAT (i.e. greater use of small 
field segments and isolated beamlets).    The study should focus on patients with various 
tumour sizes (0.25 cm up to 5 cm in diameter) and locations (e.g. central vs. peripheral 
lung).  Further, to assess the benefits of gated treatment, LED-VMAT dose distributions 
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should be calculated using 4D-CT data from different phases of the respiratory cycle (e.g. 
inspiration vs. expiration).  Using gated beams at inspiration phases of respiration would 
create new opportunities for forcing LED.  From this analysis, we could determine the 
limitations of LED-VMAT, and identify a sub-set of patients that could most likely 
benefit from this technique. 
 The second phase of the study should resolve questions concerning practical 
treatment planning and delivery.  The ability of various algorithms (e.g. collapsed-cone 
convolution) to accurately calculate dose distributions under conditions of extreme LED 
will be assessed against Monte Carlo results using LED-VMAT.  As noted above, in 
Chapter 3 we hypothesized that dosimetric effects of LED-VMAT could be further 
accentuated if treatment were delivered during the inhale phase of the respiratory cycle 
(i.e. gating radiation treatment).  Unfortunately, gating LED-VMAT will result in longer 
treatment session times; an issue that could be overcome using a Truebeam LINAC, 
where dose rates are up to 4 times higher compared to traditional LINAC technology[14].  
In addition, the inhale phase of the breathing cycle is less stable in comparison to the 
exhale conditions more often used. 
 In the final phase, patients would be enrolled into a longitudinal pilot clinical 
study to test the ability of LED-VMAT to improve outcomes for early-staged lung cancer 
patients.  LED-VMAT can produce very steep dose gradients to enhance tumour dose 
levels, while maintaining and/or reducing normal lung dose.  This may be perceived as 
controversial by the community, as some authors may prefer the use of lower, more 
homogeneous dose distributions instead [15].  We could resolve this controversy by 
tracking improvements in tumour control, and overall patient survival for homogeneous 
versus inhomogeneous tumour dose patterns.  Further, we will also assess the ability of 
LED-VMAT to avoid healthy structures, typically subject to high grade toxicities from 
standard SBRT treatment (e.g. ribs, esophagus, trachea, and bronchi). 
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5.2.4 Cone-beam CT image-guided Adaptive SBRT 
In the fourth chapter of thesis, we proposed CT number corrective techniques to improve 
the accuracy of CBCT numbers by selective substitution.  We recommended the use of a 
LED-sensitive CT number (LCT) substitute to replace CBCT lung pixels that artificially 
create LED.  In this analysis, we tested the LCT method to correct CBCT images of only 
three patients, and found that dose calculations became comparable to PCT based results.  
Further, we suggested an expedited five step process to implement the correction 
technique clinically, to allow for ‘on the fly’ adaptive dose calculations.  However, the 
accuracy and limitations of the LCT correction method should be tested in a larger 
population of patients with various tumour sizes and locations.  Further, the efficiency of 
the envisioned five step process could be tested in a time-tracking study. 
 An alternative solution to this problem could be to scan a tissue equivalent, 
deformable lung calibration phantom [16] using CBCT thorax scan settings.  With such a 
dynamic phantom, CBCT image artefacts observed in phantom scans may become more 
comparable to those seen in patient images, and a more accurate HU-to-RED curve may 
be obtained.  4D-CT imaging could also be used to determine dynamic changes in density 
as a function of time during gated or un-gated beam delivery. 
  
5.2.5 Assessing the prevalence of LED susceptibility in a 
population of lung cancer patients treated by SBRT  
Throughout the chapters of this thesis we have emphasized that LED can potentially 
reduce or enhance the dose within tumour tissues for SBRT treatment of early-staged 
lung cancer.  Further, as this phenomenon may be poorly accounted for by clinical dose 
calculation algorithms, treatment prescriptions and clinical trials outcomes could be 
misleading or ambiguous.  To further assess the validity of this statement, we must first 
determine the prevalence of LED for a group of SBRT lung patients.  This could be done 
by retrospectively analyzing CT data from previously irradiated lung patients.  In this 
analysis, patient lung density will be acquired from 4D-CT data.  Using the physics 
knowledge learned from chapter 2, we will determine the specific lung densities that 
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create LED for commonly used SBRT beam parameters [e.g. 6 MV (3x3 cm
2
)].  From 
this investigation, we will be able to approximate the number of SBRT lung cancer 
patients who are likely to be affected by LED considerations.   
 Future patients can be triaged for improved treatment planning that accounts for 
regional dose reductions due to LED. The ultimate goal remains to deliver tumour-
controlling doses with minimal side effects for patients otherwise facing invasive surgery 
and a very poor prognosis.  It is hoped that the publications from this thesis will raise 
community awareness to a new positive facet of LED - offering a new degree of freedom 
that might yield a better chance at a cure while maintaining good quality of life for lung 
cancer patients. 
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